Medical Marijuana Workgroup Report (2012)

Final Report of the
Medical Marijuana Model Program Workgroup
Dear President Miller, Speaker Busch, Chair Frosh, Chair Vallario and Chair Hammen:
As chair of the medical marijuana model program workgroup, I am respectfully submitting to you the final report of the workgroup required by Senate Bill 308, Chapter 215 of the
2011 legislative session.
Our group met three times, and teams within the workgroup met another five times.
Through multiple meetings and discussions, it became clear that workgroup members held different perspectives on some core issues – including the role of the academic research
institution.
Toll Free 1-877-4MD-DHMI-1 – TTY/Maryland Relay Service l-800-735-2258
Web Site: www.dhinh.state.md.us
Senate Bill 308, Chapter 215 (2011) – Final Report of the Medical Marijuana Model Program Workgroup
Page 2
The group decided to provide two different proposals to the legislature – each to be signed by those members of the workgroup in support. Workgroup members were able to sign on to one or both of the proposals. Workgroup member Michael Young chose not to sign on to either proposal.
Proposal 1 is supported by the following workgroup members:● Major Kevin Anderson ● Dr. Trudy Hall
● Major Sam Billotti ●Dr. Joseph Liberto
● Dario Broccolino ●Dr. Nancy Rosen-Cohen
● Dr. Paul Celano ● Dr. Joshua Sharfstein
● Philip Cogan ● Dr. Ryan Vandrey
● Delegate Kathleen Dumais 
Proposal 2 is supported by the following workgroup members:● Lynn Billing ●Deborah Miran
● Senator David Brinkley ●Delegate Dan Morhaim
● Dario Broccolino ●Karen O’Keefe
● Philip Cogan ● Senator Jamie Raskin
● Delegate Kathleen Dumais ●Dr. Ryan Vandrey
I appreciate the work and input of all of the members of the workgroup, and look forward to working with the General Assembly on this issue during the 2012 legislative session. If you have any questions, please contact me or Ms. Marie Grant at 410-767-6480.
Sincerely,
Joshua M. Sharfstein, M.D. Secretary
Enclosure
cc: Medical Marijuana Model Program Workgroup Members
Virginia Geckler, Governor’s Office of Crime Control and Prevention Erin Hopwood, House Health and Government Operations Committee Staff Kristen Mahoney, Governor’s Office of Crime Control and Prevention Shirleen Pilgrim, Senate Judicial Proceedings Committee Staff Claire Rossmark, House Judiciary Committee Staff Marie Grant, Director of Governmental Affairs Sarah Albert, Department of Legislative Services, MSAR# 8946
   
  Medical Marijuana Model Program Workgroup    
Proposal 1  Medical Marijuana Model Program Workgroup – Proposal 1   
Introduction  
  Senate Bill 308 of 2011 (Chapter 215) required the Secretary of Health and Mental Hygiene to  convene a workgroup to develop and assess the feasibility of a State specific proposal for providing  access to marijuana to patients in the State for medical purposes.      The legislation requires the workgroup to present draft legislation that outlines the key elements of  the model program and includes provisions that:    
● Provide for oversight and responsibility by programs located in academic medical research  institutions in the State; 
● Provide for the licensing of a program by the State;  
● Establish a program application and review process that includes consideration of best  practices and procedures for obtaining review input that is external to the Department of  Health and Mental Hygiene;  
● Expand the base of information on the use of marijuana for medical purposes on a scientific  and policy implementation basis; and  
● Implement a program as soon as feasible, with goals of implementation by January 2013.  
      Senate Bill 308 also requires the workgroup to provide guidance on the criteria for assessing  program applications, including an applying program’s plans for:    
● Determining the medical conditions to be treated and the duration of therapy proposed;  
● Identifying sources of marijuana;  
● Determining patient eligibility and informed consent;  
● Conducting any associated research projects;  
● Reporting data and outcomes;  
● Instituting strict controls against illegal diversion; and  
● Securing grants or other sources of funding to facilitate the affordability of the program.     Senate Bill 308 requires the Secretary of Health and Mental Hygiene to report on the findings of the  workgroup to the Senate Judicial Proceedings Committee, the House Health and Government  Operations Committee, and the House Judiciary Committee on the findings of the workgroup.     This proposal, Proposal 1, is one of two proposals developed by the workgroup to address the  requirements of Senate Bill 308.      
Framework 
  The framework for this approach to marijuana for medical uses is that marijuana is not a  conventionally accepted treatment in medicine.  It does not have approval from the U.S. Food and  Drug Administration and its use is not recommended by major professional associations, such as  the American Medical Association or the American College of Physicians.  These organizations have  called for additional research and recognize that marijuana has both potential benefits and  potential risks for patients.  The benefits include the alleviation of certain debilitating symptoms,  and the risks include psychiatric and behavioral side effects and addiction.      
When it is not clear whether the benefits exceed the risks of a therapy, institutions often are able to  make this therapy available to patients in an “investigational use” setting.  This has also been  referred to as “compassionate use.”  In its comprehensive review of marijuana for medical uses, the  Institute of Medicine endorsed this type of approach, stating:  Short term use of smoked marijuana (less than six months) for patients with debilitating  symptoms (such as intractable pain or vomiting) must meet the following conditions:   
● Failure of all approved medications to provide relief has been documented; 
● The symptoms can reasonably be expected to be relieved by rapid onset      cannabinoid drugs; 
● Such treatment is administered under medical supervision in a manner that     allows for assessment of treatment effectiveness, and 
● Involves an oversight strategy comparable to an institutional review board process     that could provide guidance within 24 hours of a submission by a physician to     provide marijuana to a patient for a specified use. 
 
Recommendations 
  The members of the Workgroup that have signed on to this proposal have made recommendations  in four areas:  process, science, diversion, and other. 
                                                       
Table 1:  Process Recommendations   Recommendation   Comments  
1  Marijuana for medical uses may be made 
available through approved investigational 
use programs overseen by academic medical 
research institutions.  The term “academic medical research 
institution” refers to hospitals that have 
medical residency programs for physicians 
and conduct research involving human 
subjects overseen by the Department of Health 
and Human Services. 
2  There should be an oversight entity that 
develops a RFP consistent with the other 
recommended requirements of this report.   This group should either be an advisory group 
to the Department of Health and Mental 
Hygiene (with final approval by the 
Department) or an independent group 
established along the lines of a professional 
licensing board. 
3  The academic medical research institution 
should pay an application fee and an annual 
license fee to recoup the costs of the 
application process and oversight. The 
application fee should be set by the entity 
reviewing the applications and the annual fee 
by the entity responsible for oversight.  State funds for new programs are limited, and 
the licensing of medical marijuana programs 
must be cost neutral to the State.  
4  The oversight entity will arrange for expert 
review of applications.  This review should 
include an assessment of risks and benefits 
with regards to the medical condition to be 
treated, patient inclusion and monitoring, 
data collection and reporting, and monitoring 
for diversion.    Experts will submit application reviews to the 
oversight entity for consideration in making a 
final decision on the application.  
5  The oversight entity should be responsible for 
ensuring that the academic medical research 
institutions meet their responsibilities under 
the application.  This should include inspections of approved 
programs by the oversight entity.  
6  There should be annual renewal of licensure 
by academic medical research institution.   This review should not be pro forma.  
Continued approval should be based on 
meeting the goals of the application and 
providing all appropriate data.  
7  There should be an annual report by each 
academic medical research institution 
licensed for medical marijuana programs, as 
well as a public report.   Annual reports should include information on 
the number of patients served, the county of 
residence of the patients, the conditions 
treated, outcome data, and any research 
studies conducted under the medical 
marijuana program.  The oversight entity 

  Recommendation   Comments  
  should establish standard data collection 
procedures for approved investigational use 
programs.  

Table 2:  Recommendations for the Scientific Components of Applications from Academic  Medical Research Institutions for a Medical Marijuana Program   Recommendation  Comments  
1  The application should specify the 
medical conditions to be treated, 
proposed on the basis of medical 
evidence.  This is a standard part of an investigational use 
program. 
2  The application should specify the 
criteria by which the academic 
medical research institution will 
include and exclude patients from 
participation in the program.  This is a standard part of an investigational use 
program. 
3  The application should specify how 
patients will be assessed for addiction 
before and during treatment with 
marijuana.  A history of problematic substance use should not 
necessarily exclude a prospective patient from 
participating in the program, using appropriate 
medical need considerations.  However, evaluation of 
addiction before enrollment and the emergence of 
new drug use problems following enrollment will be 
important in assessing the risks and benefits of 
participation to the patient.  
4  The application should include 
scientific details of the type of 
marijuana to be used in the program.  Characterization of a clinical intervention is a 
standard part of an investigational use program.  
There could be different types of marijuana used by 
approved programs; however, consistency of the 
characteristics for each type of marijuana used is 
essential.  
5  The application should specify the 
proposed length of treatment, dosage 
permitted under the program, and 
plan for ongoing evaluation of patient 
response.   This is a standard part of an investigational use 
program. 
6  The application must describe how 
medical providers will be eligible to 
participate in the program and detail 
the training and/or certification 
required for participation in the 
program.  Medical providers do not have to be employees or 
affiliates of the academic medical research institution.  
However, the institution must provide a list of 
providers participating in the program to the 
oversight entity.  This list does not need to be 
provided at the time of application for approval.  
7  The application should demonstrate 
approval by the institution’s IRB.   This is a standard part of an investigational use 
program.  

  Recommendation  Comments  
8  The application should describe the 
plan for defining and monitoring the 
success or failure of treatment.   This is a standard part of an investigational use 
program and is important for clinical care.  
9  The application should include a plan 
for monitoring aggregate data and 
outcomes and publishing results, as 
appropriate.   This will allow for others to learn about the outcomes 
of the program. 
10  The application should include the 
sources of funding for the initiative, 
including any research grants.   This allows the oversight entity to understand 
whether there is external scientific oversight, such as 
through a grant funder. 
  Table 3:  Recommendations for the Diversion Components of Applications from Academic  Medical Research Institutions for a Medical Marijuana Program   Recommendation  Comments  
1  The application should describe 
the source of the marijuana that 
will be used in the program.  This will allow the state to know the sources of all 
marijuana used under this program in Maryland. 
2  The application should describe 
required training for medical 
providers and patients on 
diversion related issues.  This training should reduce diversion. 
3  The application should describe 
how the programs will monitor 
for diversion.  This will allow the oversight entity to assure compliance 
with an anti diversion program. 
4  The application should describe 
how the program will address 
violations of the diversion policy.  This will assure that there are consequences within the 
program for both medical providers and patients for 
diversion. 
5  The application should describe 
any caregiver structure that will 
be used in the program, within 
limits set in the legislation.   The proposed limits in the draft legislation are that a 
caregiver is allowed to serve no more than five individuals, 
and that no more than two caregivers may serve any one 
patient.  Caregivers should have protection from 
prosecution for their role in an approved program, and 
their participation in a program should be reported to an 
electronic database available to state law enforcement.   
6  The oversight entity should add 
any other specifications for 
control of diversion by programs 
that it deems appropriate.    
  Table 4:  Other Recommendations     Recommendation  Comments  
1  Marijuana growers will be separately 
licensed by the State of Maryland. Academic 
medical research institutions can obtain 
marijuana from any grower licensed by the 
State or from the National Institute on Drug 
Abuse’s federal marijuana program.  This licensure process should focus on good 
manufacturing practices and security, including a 
product tracking system.  If a grower is not 
licensed, then its products may not be used in a 
program in the State and are subject to 
enforcement of state laws against marijuana 
cultivation.  Growers must be licensed prior to 
beginning marijuana cultivation.  
2  Academic medical research institutions 
with marijuana programs should provide 
updated data each day on enlisted patients 
to the Prescription Drug Monitoring 
Program, or an equivalent process that 
allows for access by law enforcement.    The state should make marijuana data available 
to the police in real time, with appropriate 
privacy protections, to assure both that patients 
are not penalized for access to marijuana through 
a legitimate program and to limit diversion.   
3  There should be additional state penalties 
for gross misuse of a marijuana program 
for diversion purposes.   
4  Patients participating in an approved 
marijuana program should not be subject to 
arrest, prosecution, or criminal penalty for 
possession of medical marijuana obtained 
through the program.    
5  There should be protections from arrest 
and prosecution for academic medical 
research institutions, growers, and their 
staff for participation in an approved 
medical marijuana program.    
    Workgroup Members Signing on to Proposal 1 
  The following members of the workgroup signed on to Proposal 1:    
● Major Kevin Anderson  
● Major Sam Billotti  
● Dario Broccolino 
● Dr. Paul Celano  
● Philip Cogan  
● Delegate Kathleen Dumais  
● Dr. Trudy Hall 
● Dr. Joseph Liberto  
● Dr. Nancy Rosen Cohen  
● Dr. Joshua Sharfstein  
● Dr. Ryan Vandrey 
   
Model Legislation to Implement Proposal 1 
  Two versions of draft legislation are included here.  The first version provides for oversight to be  conducted by the Department of Health and Mental Hygiene, with the assistance of an Advisory  Committee.  The second version provides for oversight to be conducted by an independent  commission.  
  Version 1.  DHMH and Advisory Committee Oversight. 
 
SECTION 1.  BE IT ENACTED BY THE GENERAL ASSEMBLY OF  MARYLAND, That the Laws of Maryland read as follows: 
Article – Health – General 
SUBTITLE 31. MEDICAL MARIJUANA ADVISORY COMMITTEE.
13-3101.
(A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS  INDICATED.
(B) “ACADEMIC MEDICAL CENTER” MEANS A HOSPITAL THAT:
(1) OPERATES A MEDICAL RESIDENCY PROGRAM FOR PHYSICIANS; AND
(2) CONDUCTS RESEARCH THAT IS OVERSEEN BY THE
FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES AND INVOLVES HUMAN SUBJECTS.
(C) “ADVISORY COMMITTEE” MEANS THE MEDICAL MARIJUANA ADVISORY  COMMITTEE ESTABLISHED UNDER THIS SUBTITLE.
(D) “PROGRAM” MEANS AN INVESTIGATIONAL USE-TYPE PROGRAM
OVERSEEN BY AN ACADEMIC MEDICAL CENTER THROUGH WHICH MARIJUANA IS MADE  AVAILABLE FOR MEDICAL USES TO PATIENTS.
13- 3102.
(A) THERE IS A MEDICAL MARIJUANA ADVISORY COMMITTEE IN THE  DEPARTMENT.
(B) THE PURPOSE OF THE ADVISORY COMMITTEE IS TO:
(1) DEVELOP REQUESTS FOR APPLICATIONS FOR ACADEMIC  MEDICAL CENTERS TO OPERATE PROGRAMS, IN ACCORDANCE WITH THIS SUBTITLE;
(2) MAKE RECOMMENDATIONS ON APPROVAL OR DENIAL OF  APPLICATIONS FOR PROGRAMS TO THE SECRETARY;
(3) MAKE RECOMMENDATIONS ON APPROVAL OR DENIAL OF  RENEWAL APPLICATIONS FOR APPROVAL OF PROGRAMS; AND
(4) ADVISE ON THE MONITOR AND OVERSIGHT OF PROGRAMS  APPROVED FOR OPERATION UNDER THIS SUBTITLE.
13- 3103.
(A) THE ADVISORY COMMITTEE CONSISTS OF THE FOLLOWING MEMBERS:
(1) TWO MEMBERS OF THE MARYLAND SENATE, APPOINTED BY THE  PRESIDENT OF THE SENATE;
(2) TWO MEMBERS OF THE MARYLAND HOUSE OF DELEGATES, APPOINTED BY THE SPEAKER OF THE HOUSE OF DELEGATES; AND
(3) THE FOLLOWING MEMBERS, APPOINTED BY THE GOVERNOR:
(I)  ONE MEMBER OF THE PUBLIC WHO SUPPORTS THE USE OF  MARIJUANA FOR MEDICAL PURPOSES;
(II)  ONE MEMBER OF THE PUBLIC DESIGNATED BY THE MARYLAND  CHAPTER OF THE NATIONAL COUNCIL ON ALCOHOLISM AND DRUG DEPENDENCE;
(III) THREE PHYSICIANS LICENSED IN THE STATE, WHO SPECIALIZE IN  ADDICTION, PAIN, ONCOLOGY, NEUROLOGY, OR CLINICAL RESEARCH;
(IV)  ONE NURSE LICENSED IN THE STATE, WITH EXPERIENCE IN  HOSPICE CARE, NOMINATED BY A STATE RESEARCH INSTITUTION OR TRADE  ASSOCIATION;
(V)  ONE PHARMACIST LICENSED IN THE STATE, NOMINATED BY A  STATE RESEARCH INSTITUTION OR TRADE ASSOCIATION;
(VI)  ONE SCIENTIST WITH EXPERIENCE IN THE SCIENCE OF MARIJUANA, NOMINATED BY A STATE RESEARCH INSTITUTION;
(VII) ONE REPRESENTATIVE OF THE MARYLAND STATE’S ATTORNEYS’ ASSOCIATION;
(VIII) ONE REPRESENTATIVE OF THE MARYLAND CHIEFS OF POLICE;
(IX)  ONE REPRESENTATIVE OF THE MARYLAND SHERIFFS’ ASSOCIATION;
(X)  ONE REPRESENTATIVE OF THE MARYLAND FRATERNAL ORDER  OF POLICE; AND
(XI)  AN ATTORNEY WHO IS KNOWLEDGEABLE ABOUT MEDICAL  MARIJUANA LAWS IN THE UNITED STATES.
(B) (1) THE TERM OF AN APPOINTED MEMBER IS 2 YEARS.
(2)  THE TERMS OF THE APPOINTED MEMBERS ARE STAGGERED AS  REQUIRED BY THE TERMS PROVIDED FOR MEMBERS ON OCTOBER 1, 2012.
(3)  AT THE END OF A TERM, AN APPOINTED MEMBER CONTINUES TO  SERVE UNTIL A SUCCESSOR IS APPOINTED AND QUALIFIES.
(4)  AN APPOINTED MEMBER MAY NOT SERVE MORE THAN THREE  CONSECUTIVE FULL TERMS.
(5)AN APPOINTED MEMBER WHO IS APPOINTED AFTER A TERM HAS
BEGUN SERVES ONLY FOR THE REST OF THE TERM AND UNTIL A SUCCESSOR IS  APPOINTED AND QUALIFIES.
(C) THE GOVERNOR SHALL DESIGNATE A CHAIR FROM AMONG THE  APPOINTED MEMBERS OF THE ADVISORY COMMITTEE.
(D) A MAJORITY OF THE FULL AUTHORIZED MEMBERSHIP OF THE ADVISORY  COMMITTEE IS A QUORUM.
(E) A MEMBER OF THE ADVISORY COMMITTEE:
(1)  MAY NOT RECEIVE COMPENSATION AS A MEMBER OF THE ADVISORY COMMITTEE; BUT
(2)  IS ENTITLED TO REIMBURSEMENT FOR EXPENSES UNDER THE  STANDARD STATE TRAVEL REGULATIONS, AS PROVIDED IN THE STATE BUDGET.
13- 3104.
(A) THE ADVISORY COMMITTEE, WITH THE CONSENT OF THE SECRETARY, SHALL ISSUE A REQUEST FOR APPLICATIONSFOR ACADEMIC MEDICAL CENTERS TO  OPERATE MEDICAL MARIJUANA COMPASSIONATE USE PROGRAMS AT LEAST  ANNUALLY.
(B)  AN APPLICATION SUBMITTED BY AN ACADEMIC MEDICAL CENTER TO  OPERATE A PROGRAM UNDER THIS SUBTITLE SHALL:
(1) SPECIFY THE MEDICAL CONDITIONS TO BE TREATED UNDER THE  PROGRAM TO BE OPERATED BY THE ACADEMIC MEDICAL CENTER, PROPOSED ON THE  BASIS OF EVIDENCE;
(2)SPECIFY THE CRITERIA BY WHICH THE ACADEMIC MEDICAL
CENTER WILL INCLUDE AND EXCLUDE PATIENTS FROM PARTICIPATION IN THE PROGRAM;
(3) SPECIFY HOW PATIENTS WILL BE ASSESSED FOR ADDICTION  BEFORE AND DURING TREATMENT WITH MARIJUANA THROUGH THE PROGRAM;
(4)DESCRIBE THE SOURCE OF MARIJUANA TO BE USED IN A
PROGRAM AND INCLUDE SCIENTIFIC DETAILS OF THE TYPE OF MARIJUANA TO BE  USED IN THE PROGRAM;
(5) SPECIFY THE LENGTH OF TREATMENT AND DOSAGE PERMITTED  UNDER THE PROGRAM;
(6) DESCRIBE HOW HEALTH CARE PROVIDERS WILL BE ELIGIBLE TO  PARTICIPATE IN THE PROGRAM AND WHAT TRAINING THEY WILL RECEIVE;
(7) INCLUDE A DESCRIPTION OF WHETHER AND HOW CAREGIVERS  WILL INTERACT WITH PATIENTS PARTICIPATING IN THE PROGRAM;
(8) DEMONSTRATE APPROVAL OF THE PROGRAM BY THE ACADEMIC MEDICAL CENTER’S INSTITUTIONAL REVIEW BOARD;
(9) DESCRIBE THE PLAN FOR DEFINING AND MONITORING THE  SUCCESS OR FAILURE OF TREATMENT WITH MARIJUANA THROUGH THE PROGRAM;
(10) INCLUDE A PLAN FOR MONITORING AGGREGATE DATA AND  OUTCOMES AND PUBLISHING RESULTS FROM THE PROGRAM, AS APPROPRIATE;
(11) INCLUDE A DESCRIPTION OF THE SOURCES OF FUNDING FOR THE  PROGRAM, INCLUDING ANY RESEARCH GRANTS;
(12) DESCRIBE ANY REQUIRED TRAINING FOR HEALTH CARE  PROVIDERS AND PATIENTS PARTICIPATING IN THE PROGRAM ON DIVERSIONRELATED ISSUES;
(13) DESCRIBE STEPS THE ACADEMIC MEDICAL CENTER WILL TAKE TO
PREVENT AND MONITOR FOR DIVERSION AND ADDRESS VIOLATIONS OF ITS  DIVERSION POLICY;
(14) DESCRIBE HOW THE PROGRAM WILL DISPOSE OF ANY  UNUSED MARIJUANA; AND
(15) DESCRIBE HOW THE ACADEMIC MEDICAL CENTER AND  THE PROGRAM WILL MEET ANY OTHER CRITERIA ESTABLISHED BY THE ADVISORY  COMMITTEE RELATED TO DIVERSION OR OTHER ASPECTS OF PROGRAMS.
(C) THE DEPARTMENT SHALL SET APPLICATION FEES AND RENEWAL FEES
THAT COVERS THE EXPENSES ASSOCIATED WITH REVIEWING AND APPROVING  APPLICATIONS AND PROVIDING OVERSIGHT TO PROGRAMS.
13-3105.
(A) THE ADVISORY COMMITTEE SHALL ESTABLISH A REVIEW PROCESS  INVOLVING REVIEWERS WITH EXPERTISE IN SCIENTIFIC RESEARCH AND ANALYSIS, MEDICAL TRAINING, AND LAW ENFORCEMENT.
(B)   THE REVIEWERS SHALL:
(1) REVIEW, EVALUATE, AND RATE APPLICATIONS FOR MEDICAL
MARIJUANA COMPASSIONATE USE PROGRAMS SUBMITTED BY ACADEMIC MEDICAL  CENTERS, BASED ON THE PROCEDURES AND GUIDELINES ESTABLISHED BY THE  ADVISORY COMMITTEE; AND
(2)  MAKE RECOMMENDATIONS TO THE ADVISORY COMMITTEE, BASED ON THE RATINGS AWARDED TO PROPOSALS BY THE REVIEWERS, FOR
APPROVAL OF APPLICATIONS FROM MEDICAL MARIJUANA COMPASSIONATE USE PROGRAMS.
(C) THE ADVISORY COMMITTEE SHALL MAKE RECOMMENDATIONS ON  APPROVAL TO THE SECRETARY.
(D) THE SECRETARY MAY GRANT A ONE-YEAR RENEWABLE LICENSE TO A  PROGRAM.
13-3106.
(A) AN ACADEMIC MEDICAL CENTER APPROVED TO OPERATE A PROGRAM  UNDER THIS SUBTITLE SHALL PROVIDE UPDATED DATA EACH DAY ON PATIENTS AND 
CAREGIVERS PARTICIPATING IN EACH PROGRAM OVERSEEN BY THE ACADEMIC  MEDICAL CENTER TO [INSERT STATE ENTITY], WHICH WILL MAKE THE DATA  AVAILABLE IN REAL TIME TO LAW ENFORCEMENT, SUBJECT TO APPROPRIATE  PRIVACY PROTECTIONS.
(B) AN ACADEMIC MEDICAL CENTER OPERATING A PROGRAM  APPROVED  UNDER THIS SUBTITLE MAY ONLY USE MARIJUANA OBTAINED FROM:
(1) THE FEDERAL GOVERNMENT; OR
(2) A MEDICAL MARIJUANA GROWER LICENSED UNDER THIS  SUBTITLE.
(C) IF THE ACADEMIC MEDICAL CENTER UTILIZES CAREGIVERS AS PART OF  A PROGRAM APPROVED UNDER THIS SUBTITLE, THE ACADEMIC MEDICAL CENTER  SHALL:
(1) LIMIT THE NUMBER OF PATIENTS A CAREGIVER IS ALLOWED TO  SERVE TO NO MORE THAN FIVE; AND
(2) LIMIT THE NUMBER OF CAREGIVERS THAT SERVE A PARTICULAR PATIENT TO NO MORE THAN TWO.
(D) AN ACADEMIC MEDICAL CENTER OPERATING A PROGRAM APPROVED  UNDER THIS SUBTITLE SHALL REPORT ANNUALLY TO THE ADVISORY COMMITTEE  AND THE DEPARTMENT, IN THE FORM SPECIFIED BY THE DEPARTMENT, ON:
(1)THE NUMBER OF PATIENTS SERVED THROUGH THE PROGRAM;
(2) THE COUNTY OF RESIDENCE OF THE PATIENTS SERVED BY THE  PROGRAM;
(3) CONDITIONS TREATED UNDER THE PROGRAM;
(4) ANY OUTCOMES DATA ON THE RESULTS OF TREATMENT THROUGH THE PROGRAM; AND
(5)ANY RESEARCH STUDIES CONDUCTED UNDER THE PROGRAM.
(E) AN ACADEMIC MEDICAL CENTER OPERATING A PROGRAM APPROVED  UNDER THIS SUBTITLE SHALL APPLY ANNUALLY TO THE DEPARTMENT FOR RENEWAL  OF APPROVAL, IN ACCORDANCE WITH ANY PROCEDURES ESTABLISHED BY THE  DEPARTMENT.
(F) AN ACADEMIC MEDICAL CENTER OPERATING A PROGRAM APPROVED  UNDER THIS SUBTITLE IS SUBJECT TO INSPECTION BY THE DEPARTMENT TO ENSURE
THAT THE PROGRAM IS OPERATING ACCORDING TO THE CONDITIONS OF APPROVAL  ESTABLISHED BY THE DEPARTMENT.
(G) THE DEPARTMENT MAY RESCIND APPROVAL OF A PROGRAM IF THE DEPARTMENT FINDS THAT THE PROGRAM IS NOT IN COMPLIANCE WITH THE  CONDITIONS OF APPROVAL ESTABLISHED BY THE DEPARTMENT.
13-3107.
ON OR BEFORE JANUARY 1 OF EACH YEAR, THE DEPARTMENT SHALL REPORT  TO THE GOVERNOR AND, IN ACCORDANCE WITH § 2-1246 OF THE STATE  GOVERNMENT ARTICLE, THE GENERAL ASSEMBLY, ON PROGRAMS APPROVED TO  OPERATE UNDER THIS SUBTITLE.
13-3108.
(A) THE [INSERT STATE ENTITY] SHALL ESTABLISH A PROCESS FOR LICENSURE OF MEDICAL MARIJUANA GROWERS TO OPERATE IN THE STATE TO
PROVIDE MARIJUANA TO PROGRAMS APPROVED FOR OPERATION UNDER THIS  SUBTITLE.
(B) MARIJUANA GROWN BY AN ENTITY LICENSED UNDER THIS SECTION MAY
PROVIDE MARIJUANA ONLY TO AN ACADEMIC MEDICAL CENTER APPROVED TO  OPERATE A PROGRAM UNDER THIS SUBTITLE.
(C) THE [INSERT STATE ENTITY] SHALL ESTABLISH REQUIREMENTS FOR
SECURITY AND MANUFACTURING PROCESS THAT A GROWER MUST MEET IN ORDER TO  OBTAIN LICENSURE UNDER THIS SECTION, INCLUDING A REQUIREMENT FOR A  PRODUCT TRACKING SYSTEM.
(D) THE [INSERT STATE ENTITY] MAY INSPECT GROWERS LICENSED UNDER  THIS SECTION TO ENSURE COMPLIANCE WITH THIS SECTION.
(E) THE [INSERT STATE ENTITY] MAY IMPOSE PENALTIES OR RESCIND THE
LICENSE OF A GROWER THAT DOES NOT MEET THE STANDARDS FOR LICENSURE SET  BY THE [INSERT STATE ENTITY].
13-1309.
(A) ANY OF THE FOLLOWING PERSONS ACTING IN ACCORDANCE WITH THE 
PROVISIONS OF THIS SUBTITLE MAY NOT BE SUBJECT TO ARREST, PROSECUTION, OR  ANY CIVIL OR ADMINISTRATIVE PENALTY, INCLUDING CIVIL PENALTY OR  DISCIPLINARY ACTION BY A PROFESSIONAL LICENSING BOARD, NOR BE DENIED ANY  RIGHT OR PRIVILEGE, FOR THE MEDICAL USE OF MARIJUANA:
(1)A PATIENT ENROLLED IN A PROGRAM APPROVED UNDER THIS
SUBTITLE WHO IS IN POSSESSION OF AN AMOUNT OF MARIJUANA AUTHORIZED UNDER  THE PROGRAM;
(2)A GROWER LICENSED UNDER § 13-3108 OF THIS SUBTITLE OR AN
EMPLOYEE OF THE LICENSED GROWER WHO IS ACTING IN ACCORDANCE WITH THE TERMS OF THE LICENSE;
(3) AN ACADEMIC MEDICAL CENTER, AN EMPLOYEE OF THE  ACADEMIC MEDICAL CENTER, OR ANY OTHER PERSON ASSOCIATED WITH THE
OPERATION OF A PROGRAM APPROVED UNDER THIS SUBTITLE FOR ACTIVITIES  CONDUCTED IN ACCORDANCE WITH THE PROGRAM APPROVED UNDER THIS SUBTITLE.
  (B) (1) A PERSON MAY NOT DISTRIBUTE, POSSESS, MANUFACTURE, OR  USE MARIJUANA THAT HAS BEEN DIVERTED FROM A PROGRAM APPROVED UNDER  THIS SUBTITLE OR FROM A PATIENT WHO IS ENROLLED IN A PROGRAM APPROVED  UNDER THIS SUBTITLE.
(2) A PERSON WHO VIOLATES THIS SUBSECTION IS GUILTY OF A  FELONY AND ON CONVICTION IS SUBJECT TO IMPRISONMENT NOT EXCEEDING 5 YEARS OR A FINE NOT EXCEEDING $10,000 OR BOTH.
(3) THE PENALTY UNDER THIS SUBSECTION IS IN ADDITION TO ANY  PENALTIES THAT A PERSON MAY BE SUBJECT TO FOR MANUFACTURE, POSSESSION, OR DISTRIBUTION OF MARIJUANA UNDER THE CRIMINAL LAW ARTICLE.
13-3010.
(A) THIS SUBTITLE MAY NOT BE CONSTRUED TO AUTHORIZE ANY INDIVIDUAL  TO ENGAGE IN THE FOLLOWING, AND IT DOES NOT PREVENT THE IMPOSITION OF ANY  CIVIL, CRIMINAL, OR OTHER PENALTIES FOR THE FOLLOWING:
(1) UNDERTAKE ANY TASK UNDER THE INFLUENCE OF MARIJUANA, WHEN DOING SO WOULD CONSTITUTE NEGLIGENCE OR PROFESSIONAL MALPRACTICE;
(2) OPERATE, NAVIGATE, OR BE IN ACTUAL PHYSICAL CONTROL OF  ANY MOTOR VEHICLE, AIRCRAFT, OR BOAT WHILE UNDER THE INFLUENCE OF  MARIJUANA;
(3) SMOKE MARIJUANA IN ANY PUBLIC PLACE;
(4) SMOKE MARIJUANA IN A MOTOR VEHICLE; OR
(5)SMOKE MARIJUANA ON A PRIVATE PROPERTY THAT:
(I) 1.  IS RENTED FROM A LANDLORD; AND
2. IS SUBJECT TO A POLICY THAT PROHIBITS THE SMOKING OF MARIJUANA ON THE PROPERTY; OR
(II) IS SUBJECT TO A POLICY THAT PROHIBITS THE SMOKING OF
MARIJUANA ON THE PROPERTY OF AN ATTACHED DWELLING ADOPTED BY ONE OF  THE FOLLOWING ENTITIES:
1. THE BOARD OF DIRECTORS OF THE COUNCIL OF  UNIT OWNERS OF A CONDOMINIUM REGIME; OR
2.  THE GOVERNING BODY OF A HOMEOWNER’S
ASSOCIATION.
(B) THIS SUBTITLE MAY NOT BE CONSTRUED TO PROVIDE IMMUNITY TO A  PERSON WHO VIOLATES THE PROVISIONS OF THIS SUBTITLE FROM CRIMINAL  PROSECUTION FOR A VIOLATION OF ANY LAW PROHIBITING OR REGULATING THE USE, POSSESSION, DISPENSING, DISTRIBUTION, OR PROMOTION OF CONTROLLED DANGEROUS SUBSTANCES, DANGEROUS DRUGS, DETRIMENTAL DRUGS, OR HARMFUL DRUGS, OR ANY CONSPIRACY OR ATTEMPT TO COMMIT ANY OF THOSE OFFENSES. Version 2.  Independent Commission Oversight. 
 
SECTION 1.  BE IT ENACTED BY THE GENERAL ASSEMBLY OF  MARYLAND, That the Laws of Maryland read as follows: 
Article – Health – General 
SUBTITLE 31. MEDICAL MARIJUANA COMMISSION
13-3101.
(A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS  INDICATED.
(B) “ACADEMIC MEDICAL CENTER” MEANS A HOSPITAL THAT:
(1) OPERATES A MEDICAL RESIDENCY PROGRAM FOR PHYSICIANS; AND
(2) CONDUCTS RESEARCH THAT IS OVERSEEN BY THE
FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES AND INVOLVES HUMAN SUBJECTS.
(C) “COMMISSION” MEANS THE MEDICAL MARIJUANA COMMISSION ESTABLISHED UNDER THIS SUBTITLE.
(D) “PROGRAM” MEANS AN INVESTIGATIONAL USE-TYPE PROGRAM
OVERSEEN BY AN ACADEMIC MEDICAL CENTER THROUGH WHICH MARIJUANA IS MADE  AVAILABLE FOR MEDICAL USES TO PATIENTS.
13- 3102.
(A) THERE IS A MEDICAL MARIJUANA COMMISSION [IN THE DEPARTMENT].
(B) THE PURPOSE OF THE COMMISSION IS TO:
(1) DEVELOP REQUESTS FOR APPLICATIONS FOR ACADEMIC  MEDICAL CENTERS TO OPERATE PROGRAMS, IN ACCORDANCE WITH THIS SUBTITLE;
(2) APPROVE OR DENY APPLICATIONS FOR PROGRAMS;
(3) APPROVE OR DENY RENEWAL APPLICATIONS FOR APPROVAL OF PROGRAMS; AND
(4) MONITOR AND OVERSEE PROGRAMS APPROVED FOR OPERATION  UNDER THIS SUBTITLE.
13- 3103.
(A) THE COMMISSION CONSISTS OF THE FOLLOWING MEMBERS:
(1) TWO MEMBERS OF THE MARYLAND SENATE, APPOINTED BY THE  PRESIDENT OF THE SENATE;
(2) TWO MEMBERS OF THE MARYLAND HOUSE OF DELEGATES, APPOINTED BY THE SPEAKER OF THE HOUSE OF DELEGATES; AND
(3) THE FOLLOWING MEMBERS, APPOINTED BY THE GOVERNOR:
(I)  ONE MEMBER OF THE PUBLIC WHO SUPPORTS THE USE OF  MARIJUANA FOR MEDICAL PURPOSES;
(II)  ONE MEMBER OF THE PUBLIC DESIGNATED BY THE MARYLAND  CHAPTER OF THE NATIONAL COALITION ON ALCOHOL AND OTHER DRUG  DEPENDENCIES COUNCIL ON ALCOHOLISM AND DRUG DEPENDENCE;
(III) THREE PHYSICIANS LICENSED IN THE STATE, WHO SPECIALIZE IN  ADDICTION, PAIN, ONCOLOGY, NEUROLOGY, OR CLINICAL RESEARCH;
(IV)  ONE NURSE LICENSED IN THE STATE, WITH EXPERIENCE IN  HOSPICE CARE, NOMINATED BY A STATE RESEARCH INSTITUTION OR TRADE  ASSOCIATION;
(V)  ONE PHARMACIST LICENSED IN THE STATE, NOMINATED BY A  STATE RESEARCH INSTITUTION OR TRADE ASSOCIATION;
(VI)  ONE SCIENTIST WITH EXPERIENCE IN THE SCIENCE OF MARIJUANA, NOMINATED BY A STATE RESEARCH INSTITUTION;
(VII) ONE REPRESENTATIVE OF THE MARYLAND STATE’S ATTORNEYS’ ASSOCIATION;
(VIII) ONE REPRESENTATIVE OF THE MARYLAND CHIEFS OF POLICE;
(IX)  ONE REPRESENTATIVE OF THE MARYLAND SHERIFFS’
ASSOCIATION;
(X)  ONE REPRESENTATIVE OF THE MARYLAND FRATERNAL ORDER  OF POLICE; AND
(XI)  AN ATTORNEY WHO IS KNOWLEDGEABLE ABOUT MEDICAL  MARIJUANA LAWS IN THE UNITED STATES.
(B) (1) THE TERM OF AN APPOINTED MEMBER IS 2 YEARS.
(2)  THE TERMS OF THE APPOINTED MEMBERS ARE STAGGERED AS  REQUIRED BY THE TERMS PROVIDED FOR MEMBERS ON OCTOBER 1, 2012.
(3)  AT THE END OF A TERM, AN APPOINTED MEMBER CONTINUES TO  SERVE UNTIL A SUCCESSOR IS APPOINTED AND QUALIFIES.
(4)  AN APPOINTED MEMBER MAY NOT SERVE MORE THAN THREE  CONSECUTIVE FULL TERMS.
(5)AN APPOINTED MEMBER WHO IS APPOINTED AFTER A TERM HAS
BEGUN SERVES ONLY FOR THE REST OF THE TERM AND UNTIL A SUCCESSOR IS  APPOINTED AND QUALIFIES.
(C) THE GOVERNOR SHALL DESIGNATE A CHAIR FROM AMONG THE  APPOINTED MEMBERS OF THE COMMISSION.
(D) A MAJORITY OF THE FULL AUTHORIZED MEMBERSHIP OF THE  COMMISSION IS A QUORUM.
(E) A MEMBER OF THE COMMISSION:
(1)  MAY NOT RECEIVE COMPENSATION AS A MEMBER OF THE COMMISSION; BUT
(2)  IS ENTITLED TO REIMBURSEMENT FOR EXPENSES UNDER THE  STANDARD STATE TRAVEL REGULATIONS, AS PROVIDED IN THE STATE BUDGET.
(F) THE COMMISSION MAY EMPLOY A STAFF, INCLUDING CONTRACTUAL  STAFF, IN ACCORDANCE WITH THE STATE BUDGET.
13- 3104.
(A) THE COMMISSION SHALL ISSUE A REQUEST FOR APPLICATIONS FOR
ACADEMIC MEDICAL CENTERS TO OPERATE MEDICAL MARIJUANA COMPASSIONATE USE PROGRAMS AT LEAST ANNUALLY.
(B)  AN APPLICATION SUBMITTED BY AN ACADEMIC MEDICAL CENTER TO  OPERATE A PROGRAM UNDER THIS SUBTITLE SHALL:
(1) SPECIFY THE MEDICAL CONDITIONS TO BE TREATED UNDER THE  PROGRAM TO BE OPERATED BY THE ACADEMIC MEDICAL CENTER, PROPOSED ON THE  BASIS OF EVIDENCE;
(2)SPECIFY THE CRITERIA BY WHICH THE ACADEMIC MEDICAL
CENTER WILL INCLUDE AND EXCLUDE PATIENTS FROM PARTICIPATION IN THE PROGRAM;
(3) SPECIFY HOW PATIENTS WILL BE ASSESSED FOR ADDICTION  BEFORE AND DURING TREATMENT WITH MARIJUANA THROUGH THE PROGRAM;
(4)DESCRIBE THE SOURCE OF MARIJUANA TO BE USED IN A
PROGRAM AND INCLUDE SCIENTIFIC DETAILS OF THE TYPE OF MARIJUANA TO BE  USED IN THE PROGRAM;
(5) SPECIFY THE LENGTH OF TREATMENT AND DOSAGE PERMITTED  UNDER THE PROGRAM;
(6) DESCRIBE HOW HEALTH CARE PROVIDERS WILL BE ELIGIBLE TO  PARTICIPATE IN THE PROGRAM AND WHAT TRAINING THEY WILL RECEIVE;
(7) INCLUDE A DESCRIPTION OF WHETHER AND HOW CAREGIVERS  WILL INTERACT WITH PATIENTS PARTICIPATING IN THE PROGRAM;
(8) DEMONSTRATE APPROVAL OF THE PROGRAM BY THE ACADEMIC MEDICAL CENTER’S INSTITUTIONAL REVIEW BOARD;
(9) DESCRIBE THE PLAN FOR DEFINING AND MONITORING THE  SUCCESS OR FAILURE OF TREATMENT WITH MARIJUANA THROUGH THE PROGRAM;
(10) INCLUDE A PLAN FOR MONITORING AGGREGATE DATA AND  OUTCOMES AND PUBLISHING RESULTS FROM THE PROGRAM, AS APPROPRIATE;
(11) INCLUDE A DESCRIPTION OF THE SOURCES OF FUNDING FOR THE  PROGRAM, INCLUDING ANY RESEARCH GRANTS;
(12) DESCRIBE ANY REQUIRED TRAINING FOR HEALTH CARE  PROVIDERS AND PATIENTS PARTICIPATING IN THE PROGRAM ON DIVERSIONRELATED ISSUES;
(13) DESCRIBE STEPS THE ACADEMIC MEDICAL CENTER WILL TAKE TO
PREVENT AND MONITOR FOR DIVERSION AND ADDRESS VIOLATIONS OF ITS  DIVERSION POLICY;
(14) DESCRIBE HOW THE PROGRAM WILL DISPOSE OF ANY  UNUSED MARIJUANA; AND
(15) DESCRIBE HOW THE ACADEMIC MEDICAL CENTER AND
THE PROGRAM WILL MEET ANY OTHER CRITERIA ESTABLISHED BY THE COMMISSION RELATED TO DIVERSION OR OTHER ASPECTS OF PROGRAMS.
(C) THE COMMISSION SHALL SET APPLICATION FEES AND RENEWAL FEES
THAT COVERS ITS EXPENSES IN REVIEWING AND APPROVING APPLICATIONS AND  PROVIDING OVERSIGHT TO PROGRAMS.
13-3105.
(A) THE COMMISSION SHALL ESTABLISH A REVIEW PROCESS WITH  REVIEWERS WITH EXPERTISE IN SCIENTIFIC RESEARCH AND ANALYSIS, MEDICAL TRAINING, AND LAW ENFORCEMENT.
(B)   THE REVIEWERS SHALL:
(1) REVIEW, EVALUATE, AND RATE APPLICATIONS FOR MEDICAL
MARIJUANA COMPASSIONATE USE PROGRAMS SUBMITTED BY ACADEMIC MEDICAL  CENTERS, BASED ON THE PROCEDURES AND GUIDELINES ESTABLISHED BY THE  COMMISSION; AND
(2)  MAKE RECOMMENDATIONS TO THE COMMISSION, BASED ON THE  RATINGS AWARDED TO PROPOSALS BY THE REVIEWERS, FOR APPROVAL OF APPLICATIONS FROM MEDICAL MARIJUANA COMPASSIONATE USE PROGRAMS.
(C) THE COMMISSION MAY GRANT A ONE-YEAR RENEWABLE LICENSE TO A  PROGRAM.
13-3106.
(A) AN ACADEMIC MEDICAL CENTER APPROVED TO OPERATE A PROGRAM  UNDER THIS SUBTITLE SHALL PROVIDE UPDATED DATA EACH DAY ON PATIENTS AND 
CAREGIVERS PARTICIPATING IN EACH PROGRAM OVERSEEN BY THE ACADEMIC  MEDICAL CENTER TO [INSERT STATE ENTITY], WHICH WILL MAKE THE DATA  AVAILABLE IN REAL TIME TO LAW ENFORCEMENT.
(B) AN ACADEMIC MEDICAL CENTER OPERATING A PROGRAM APPROVED  UNDER THIS SUBTITLE MAY ONLY USE MARIJUANA OBTAINED FROM:
(1) THE FEDERAL GOVERNMENT; OR
(2) A MEDICAL MARIJUANA GROWER LICENSED UNDER THIS  SUBTITLE.
(C) IF THE ACADEMIC MEDICAL CENTER UTILIZES CAREGIVERS AS PART OF  A PROGRAM APPROVED UNDER THIS SUBTITLE, THE ACADEMIC MEDICAL CENTER  SHALL:
(1) LIMIT THE NUMBER OF PATIENTS A CAREGIVER IS ALLOWED TO  SERVE TO NO MORE THAN FIVE; AND
(2) LIMIT THE NUMBER OF CAREGIVERS THAT SERVE A PARTICULAR PATIENT TO NO MORE THAN TWO.
(D) AN ACADEMIC MEDICAL CENTER OPERATING A PROGRAM APPROVED  UNDER THIS SUBTITLE SHALL REPORT ANNUALLY TO THE COMMISSION, IN THE FORM SPECIFIED BY THE COMMISSION, ON:
(1)THE NUMBER OF PATIENTS SERVED THROUGH THE PROGRAM;
(2) THE COUNTY OF RESIDENCE OF THE PATIENTS SERVED BY THE  PROGRAM;
(3) CONDITIONS TREATED UNDER THE PROGRAM;
(4) ANY OUTCOMES DATA ON THE RESULTS OF TREATMENT THROUGH THE PROGRAM; AND
(5)ANY RESEARCH STUDIES CONDUCTED UNDER THE PROGRAM.
(E) AN ACADEMIC MEDICAL CENTER OPERATING A PROGRAM APPROVED  UNDER THIS SUBTITLE SHALL APPLY ANNUALLY TO THE COMMISSION FOR RENEWAL  OF APPROVAL OF THE PROGRAM, IN ACCORDANCE WITH ANY PROCEDURES  ESTABLISHED BY THE COMMISSION.
(F) AN ACADEMIC MEDICAL CENTER OPERATING A PROGRAM APPROVED  UNDER THIS SUBTITLE IS SUBJECT TO INSPECTION BY THE COMMISSION TO ENSURE  THAT THE PROGRAM IS OPERATING ACCORDING TO THE CONDITIONS OF APPROVAL  ESTABLISHED BY THE COMMISSION.
(G) THE COMMISSION MAY RESCIND APPROVAL OF A PROGRAM IF THE COMMISSION FINDS THAT THE PROGRAM IS NOT IN COMPLIANCE WITH THE CONDITIONS OF APPROVAL ESTABLISHED BY THE COMMISSION.
13-3107.
ON OR BEFORE JANUARY 1 OF EACH YEAR, THE COMMISSION SHALL REPORT  TO THE GOVERNOR AND, IN ACCORDANCE WITH § 2-1246 OF THE STATE  GOVERNMENT ARTICLE, THE GENERAL ASSEMBLY, ON PROGRAMS APPROVED TO  OPERATE UNDER THIS SUBTITLE.
13-3108.
(A) THE [INSERT STATE ENTITY] SHALL LICENSE MEDICAL MARIJUANA  GROWERS TO OPERATE IN THE STATE TO PROVIDE MARIJUANA TO PROGRAMS  APPROVED FOR OPERATION UNDER THIS SUBTITLE.
(B) MARIJUANA GROWN BY AN ENTITY LICENSED UNDER THIS SECTION MAY
PROVIDE MARIJUANA ONLY TO AN ACADEMIC MEDICAL CENTER APPROVED TO  OPERATE A PROGRAM UNDER THIS SUBTITLE.
(C) THE [INSERT STATE ENTITY] SHALL ESTABLISH REQUIREMENTS FOR
SECURITY AND MANUFACTURING PROCESS THAT A GROWER MUST MEET IN ORDER TO  OBTAIN LICENSURE UNDER THIS SECTION, INCLUDING A REQUIREMENT FOR A  PRODUCT TRACKING SYSTEM.
(D) THE [INSERT STATE ENTITY] MAY INSPECT GROWERS LICENSED UNDER  THIS SECTION TO ENSURE COMPLIANCE WITH THIS SECTION.
(E) THE [INSERT STATE ENTITY] MAY IMPOSE PENALTIES OR RESCIND THE
LICENSE OF A GROWER THAT DOES NOT MEET THE STANDARDS FOR LICENSURE SET  BY THE [INSERT STATE ENTITY].
13-1309.
(A) ANY OF THE FOLLOWING PERSONS ACTING IN ACCORDANCE WITH THE  PROVISIONS OF THIS SUBTITLE MAY NOT BE SUBJECT TO ARREST, PROSECUTION, OR  ANY CIVIL OR ADMINISTRATIVE PENALTY, INCLUDING CIVIL PENALTY OR  DISCIPLINARY ACTION BY A PROFESSIONAL LICENSING BOARD, NOR BE DENIED ANY  RIGHT OR PRIVILEGE, FOR THE MEDICAL USE OF MARIJUANA:
(1)A PATIENT ENROLLED IN A PROGRAM APPROVED UNDER THIS
SUBTITLE WHO IS IN POSSESSION OF AN AMOUNT OF MARIJUANA AUTHORIZED UNDER  THE PROGRAM;
(2)A GROWER LICENSED UNDER § 13-3108 OF THIS SUBTITLE OR AN
EMPLOYEE OF THE LICENSED GROWER WHO IS ACTING IN ACCORDANCE WITH THE TERMS OF THE LICENSE;
(3) AN ACADEMIC MEDICAL CENTER, AN EMPLOYEE OF THE  ACADEMIC MEDICAL CENTER, OR ANY OTHER PERSON ASSOCIATED WITH THE
OPERATION OF A PROGRAM APPROVED UNDER THIS SUBTITLE FOR ACTIVITIES  CONDUCTED IN ACCORDANCE WITH THE PROGRAM APPROVED UNDER THIS SUBTITLE.
  (B) (1) A PERSON MAY NOT DISTRIBUTE, POSSESS, MANUFACTURE, OR  USE MARIJUANA THAT HAS BEEN DIVERTED FROM A PROGRAM APPROVED UNDER  THIS SUBTITLE OR FROM A PATIENT WHO IS ENROLLED IN A PROGRAM APPROVED  UNDER THIS SUBTITLE.
(2) A PERSON WHO VIOLATES THIS SUBSECTION IS GUILTY OF A  FELONY AND ON CONVICTION IS SUBJECT TO IMPRISONMENT NOT EXCEEDING 5 YEARS OR A FINE NOT EXCEEDING $10,000 OR BOTH.
(3) THE PENALTY UNDER THIS SUBSECTION IS IN ADDITION TO ANY  PENALTIES THAT A PERSON MAY BE SUBJECT TO FOR MANUFACTURE, POSSESSION, OR DISTRIBUTION OF MARIJUANA UNDER THE CRIMINAL LAW ARTICLE.
13-3010.
(A) THIS SUBTITLE MAY NOT BE CONSTRUED TO AUTHORIZE ANY INDIVIDUAL  TO ENGAGE IN THE FOLLOWING, AND IT DOES NOT PREVENT THE IMPOSITION OF ANY  CIVIL, CRIMINAL, OR OTHER PENALTIES FOR THE FOLLOWING:
(1) UNDERTAKE ANY TASK UNDER THE INFLUENCE OF MARIJUANA, WHEN DOING SO WOULD CONSTITUTE NEGLIGENCE OR PROFESSIONAL MALPRACTICE;
(2) OPERATE, NAVIGATE, OR BE IN ACTUAL PHYSICAL CONTROL OF  ANY MOTOR VEHICLE, AIRCRAFT, OR BOAT WHILE UNDER THE INFLUENCE OF  MARIJUANA;
(3) SMOKE MARIJUANA IN ANY PUBLIC PLACE;
(4) SMOKE MARIJUANA IN A MOTOR VEHICLE; OR
(5)SMOKE MARIJUANA ON A PRIVATE PROPERTY THAT:
(I) 1.  IS RENTED FROM A LANDLORD; AND
2. IS SUBJECT TO A POLICY THAT PROHIBITS THE SMOKING OF MARIJUANA ON THE PROPERTY; OR
(II) IS SUBJECT TO A POLICY THAT PROHIBITS THE SMOKING OF
MARIJUANA ON THE PROPERTY OF AN ATTACHED DWELLING ADOPTED BY ONE OF  THE FOLLOWING ENTITIES:
1. THE BOARD OF DIRECTORS OF THE COUNCIL OF  UNIT OWNERS OF A CONDOMINIUM REGIME; OR
2.  THE GOVERNING BODY OF A HOMEOWNER’S
ASSOCIATION.
(B) THIS SUBTITLE MAY NOT BE CONSTRUED TO PROVIDE IMMUNITY TO A  PERSON WHO VIOLATES THE PROVISIONS OF THIS SUBTITLE FROM CRIMINAL  PROSECUTION FOR A VIOLATION OF ANY LAW PROHIBITING OR REGULATING THE USE, POSSESSION, DISPENSING, DISTRIBUTION, OR PROMOTION OF CONTROLLED DANGEROUS SUBSTANCES, DANGEROUS DRUGS, DETRIMENTAL DRUGS, OR HARMFUL  DRUGS, OR ANY CONSPIRACY OR ATTEMPT TO COMMIT ANY OF THOSE OFFENSES.  
 
  Medical Marijuana Model Program Workgroup   
Proposal 2  Medical Marijuana Model Program Workgroup – Proposal 2   
 
Introduction 
  Senate Bill 308 of 2011 (Chapter 215) required the Secretary of Health and Mental Hygiene to  convene a workgroup to develop and assess the feasibility of a State specific proposal for providing  access to marijuana to patients in the State for medical purposes.     The legislation requires the workgroup to present draft legislation that outlines the key elements of  the model program and includes provisions that: 
● Provide for oversight and responsibility by programs located in academic medical research  institutions in the State; 
● Provide for the licensing of a program by the State; 
● Establish a program application and review process that includes consideration of best  practices and procedures for obtaining review input that is external to the Department of  Health and Mental Hygiene; 
● Expand the base of information on the use of marijuana for medical purposes on a scientific  and policy implementation basis; 
● Implement a program as soon as feasible, with the goal of implementation by January 2013.    Senate Bill 308 also requires the workgroup to provide guidance on the criteria for assessing  program applications, including an applying program’s plans for: 
● Determining the medical conditions to be treated and the duration of therapy proposed; 
● Identifying sources of marijuana; 
● Determining patient eligibility and informed consent; 
● Conducting any associated research projects; 
● Reporting data and outcomes; 
● Instituting strict controls against illegal diversion; and  
● Securing grants or other sources of funding to facilitate the affordability of the program.      Senate Bill 308 requires the Secretary of Health and Mental Hygiene to report on the findings of the  workgroup to the Senate Judicial Proceedings Committee, the House Health and Government  Operations Committee, and the House Judiciary Committee.    This proposal, Proposal 2, is one of two proposals developed by the workgroup to address the  requirements of Senate Bill 308.    
Framework  
  The framework for this approach to marijuana for medical uses includes a recognition that the  Maryland General Assembly has determined that patients who find relief from medical marijuana  should not be criminalized for doing so. Maryland has removed criminal penalties for patients who  prove they have serious medical conditions and that other medications have not provided relief, or  for whom side effects from other medications or treatments are too severe. Currently, these  patients have no safe means of obtaining marijuana and must instead obtain it from the illegal  market or risk a felony criminal conviction by cultivating it. In addition, patients may still be  arrested and face a criminal trial. This workgroup was established to create model legislation that  includes a means of access for patients.      Because of many regulatory hurdles, including those related to marijuana’s status as a “Schedule I”  drug, the type of research that would be needed to make marijuana an FDA approved drug has not  taken place. The American College of Physicians noted “research expansion has been hindered by a  complicated federal approval process [and] limited availability of research grade marijuana.” The  American Medical Association and the American College of Physicians do not recommend the use of  marijuana, though they support legal protections for physicians who make such recommendations.  They have also called for additional research and recognize that marijuana has both potential  benefits and potential risks for patients. Other organizations, including the American Academy of  HIV Medicine and the American Public Health Association, have positions supporting allowing the  medical use of marijuana. The benefits of the medical use of marijuana include the alleviation of  certain debilitating symptoms, and the risks include psychiatric and behavioral side effects and  dependence. Marijuana has never caused a medically documented fatal overdose.    When sufficient research has not been conducted for a medication to receive FDA approval,  institutions are sometimes able to make this therapy available to patients in an “investigational  use” setting. This has been referred to as “compassionate use.” In its 1999 comprehensive review of  marijuana for medical uses, the Institute of Medicine endorsed this type of approach, stating:   Short term use of smoked marijuana 1  (less than six months) for patients with debilitating  symptoms (such as intractable pain or vomiting) must meet the following conditions:    
● Failure of all approved medications to provide relief has been documented; 
● The symptoms can reasonably be expected to be relieved by rapid onset cannabinoid drugs; 
● Such treatment is administered under medical supervision in a manner that allows for  assessment of treatment effectiveness; and 
● Involves an oversight strategy comparable to an institutional review board process that  could provide guidance within 24 hours of a submission by a physician to provide  marijuana to a patient for a specified use.2 
 
Recommendations 
  The workgroup members that have signed on to this proposal have made recommendations in four  areas: process, science, diversion, and other.     
                                                         1 The Institute of Medicine called for the creation of rapid onset delivery methods other than smoking. Since the  Institute’s report, smokeless vaporizers have been developed, allowing marijuana to be heated just below the point of  combustion. Clinical research has shown vaporizers to be a safe method of administration. The Institute of Medicine  report found that, “except for the harms associated with smoking, the adverse effects of marijuana use are within the  range of effects tolerated for other medications.”   2 Institute of Medicine, “Marijuana and Medicine: Assessing the Science Base,” Washington, D.C.: Institute of Medicine,  1999.  
  Table 1: Process Recommendations      Recommendation  Comments 
1  Marijuana for medical uses may be dispensed to 
patients who have been certified by a physician 
who has received training from and been certified 
by an independent oversight commission. The 
marijuana will be supplied by dispensaries or 
pharmacies registered with the independent 
commission.   This allows patients to go to their own 
physicians for clinical care, while 
ensuring that physicians have 
appropriate training and oversight. It 
avoids requiring physicians and 
academic medical centers to break 
federal law by possessing or distributing 
marijuana.  
2  Academic medical centers may register with the 
state to conduct clinical research involving human 
subjects with marijuana.   
3  An independent commission should be established 
to provide oversight, including developing a 
training program for physicians and an application 
process for physicians, academic medical centers, 
growers, dispensaries, and pharmacies that wish to 
participate, consistent with the other 
recommended requirements of this report.  This independent commission should be 
established along the lines of dozens of 
existing independent agencies in 
Maryland, including the Stadium 
Authority, Lottery Agency, Handgun 
Roster Board, and Maryland Institute for 
Emergency Medical Services Systems. 
The commission should have one or 
more paid staff, and a member of the 
AG’s office should provide legal advice to 
the commission. Membership to the 
commission could be similar to the 
membership of the medical marijuana 
workgroup to ensure input from a multi
disciplinary team that includes law 
enforcement, medical professionals, 
researchers, patients, and relevant state 
agencies. 
4  The costs of oversight shall be funded by one or 
more of the following: grants; registration fees paid 
by growers, dispensaries, and participating 
pharmacies; fees paid by participating academic 
medical centers and physicians; and fees paid by 
individual patients. The initial application fee and 
annual renewal fees will be regulated by the entity 
responsible for oversight of the program.   State funds for new programs are
limited, and the regulation of medical 
marijuana programs must be cost 
neutral to the State. 
5  The oversight entity will arrange for expert review 
of all applications. If qualified experts are not on 
the oversight entity, the application may be sent to 
a separate panel of experts convened by the 
oversight entity. This will include a risk/benefit 
analysis with regards to the medical condition to 
be treated, if the symptom or condition is not one 
of those specifically enumerated in the legislation,  Experts will submit application reviews 
to the independent commission for 
consideration in making a final decision 
on the application.  

  Recommendation  Comments 
 patient inclusion/monitoring, data collection and 
reporting, and diversion monitoring.  
6  The independent commission will establish a 
program to monitor compliance among physicians 
and academic medical centers participating in the 
state medical marijuana program.  The independent commission will assess 
compliance with state regulations 
regarding the compassionate use 
program in addition to program specific 
requirements outlined in the initial 
application. 
7  There should be an annual review of registrations 
issued to physicians, academic medical research 
institutions, growers, dispensaries, and approved 
pharmacies.   This review should not be pro forma. 
Continued approval of academic medical 
centers should be based on meeting the 
goals for the application and providing 
all appropriate data. Continued approval 
of physicians should include ensuring 
that the conditions for which patients 
are receiving recommendations are 
within their clinical practice areas.  
8  There should be an annual report by each 
physician and each academic medical research 
institution licensed for medical marijuana 
programs, as well as a public report.   Annual reports should include 
information on the number of patients 
served, the county of residence of the 
patients, the conditions treated, 
outcome data, and, for academic 
research programs, any research studies 
conducted under the medical marijuana 
program.  
  Table 2: Recommendations for the Scientific Components of Applications from Certifying  Physicians and Academic Medical Research Institutions for a Medical Marijuana Program      Recommendation  Comments 
1  The applications should specify the medical 
conditions to be treated. These conditions should 
include:  
1) conditions that result in the patient being 
admitted into hospice or receiving palliative care; 
2) a chronic or debilitating disease or medical 
condition or the treatment of a chronic or 
debilitating disease or medical condition that 
produces one or more of the following: cachexia, 
anorexia, or wasting syndrome, severe or chronic 
pain, severe nausea, seizures, or severe and 
persistent muscle spasms. 
 
Conditions not listed above will be considered if 
they are included in the application and 
symptoms can reasonably be expected to be 
relieved by rapid onset cannabinoid drugs. In 
each case, the physician should believe 
recognized drugs or treatments would not be 
effective, or other treatment options would have 
more serious side effects or a greater risk of 
addiction.  
 
Physicians should document relevant information 
in the medical record.  The goal of the program is to 
provide qualifying patients with 
access. These are the conditions 
approved for an affirmative defense 
in SB 308 and which the science 
workgroup considered appropriate.  
2  The application should specify the criteria by 
which the certifying physician or academic 
medical center will include and exclude patients 
from participation in the program.   This is a standard part of an 
investigational use program. 
3  The application should specify how patients 
would be assessed for addiction before and after 
certification to participate in the program.   A history of problematic substance 
use should not exclude a 
prospective patient from 
participating in the program using 
appropriate medical need 
consideration. Evaluation of 
addiction before enrollment and the 
emergence of new drug use 
problems following enrollment will 
be important in assessing 
risk/benefits of participation to the 
patient. 
4  The application should specify the proposed
length of certifications and provide a detailed 
plan for ongoing evaluation for each medical 
condition approved within an academic medical 
center.   This is a standard part of an 
investigational use program.  

  Recommendation  Comments 
5  In the case of applications by academic medical 
centers, the applications must list individual 
medical providers participating within each 
academic medical center and must detail training 
and/or certifications required for participation.   
6  Any application that includes the conduct of 
clinical research must include a letter of approval 
from the institutional review board (IRB) 
affiliated with the academic medical center or an 
accredited independent IRB for each study to be 
conducted.  This is a standard part of an 
investigational use program.  
7  The application should describe the plan for 
defining and monitoring the success or failure of 
treatment.   This is a standard part of an 
investigational use program and is 
important for clinical care. 
8  The application should include a plan for 
monitoring aggregate data and outcomes and, in 
the case of academic medical centers, conducting 
clinical research, publishing results, as 
appropriate.  This will allow for others to learn 
about the outcomes of the program.  
    Recommendation  Comments 
1  Growers’, dispensaries’, and participating 
pharmacies’ applications should describe steps to be 
taken to prevent and monitor for drug diversion.  This will allow the independent 
commission to assure compliance 
with an anti diversion program. 
2  The application should describe how the program 
would address violations of the diversion policy.  This will ensure that there are 
consequences within the program 
for both employees of the growers 
and dispensaries and patients for 
diversion.  
3  Medical providers, pharmacies, and growers 
responsible for diversion must be dropped from the 
program immediately and reported to law 
enforcement for violations of program provisions. 
Law enforcement cannot be contacted by providers 
who suspect them of diversion due to patient 
confidentiality (HIPAA) regulations. Patients who are 
arrested or convicted of diversion related activities 
while in the program should be dropped from the 
program and, if possible, have notation in the Drug 
Monitoring Program Database. Providers/patients 
can appeal to the oversight institution for re
admission to the program.  
4  The maximum amount of marijuana that can be 
dispensed to a patient will be determined 
legislatively or by the commission.  Unlike other medications, 
physicians may not recommend 
dosage for marijuana. In addition, 
there are advantages to allowing 
patients to self titrate. The 
Canadian government approved 
prescribing information for Sativex, 
the natural marijuana extract now 
sold by prescription in Canada, 
gives patients complete freedom to 
adjust their dose as needed. The 
official pamphlet provided to 
patients specifies: “The dose you 
require is determined by you. You 
can determine the dose that best 
suits you according to the pain 
relief you experience.” 
5  The independent commission would craft regulations 
for growers and dispensaries regarding security, 
transportation, permissible locations, and labeling 
and testing to ensure consistency of the strain(s). All 
marijuana should be grown indoors with 24 7 
security. Oversight regulations would be crafted in 
consultation with state agencies.  Consistent and clear statewide 
regulations will give a clear 
mandate for maintaining safety to 
the independent commission. 

Table 3: Recommendations for the Diversion Components of Applications from Academic Medical  Research Institutions, Physicians, Growers, and Providers for a Medical Marijuana Program   
 
  Table 4: Other Recommendations      Recommendation  Comments 
1  Marijuana growers must apply and be 
separately registered by the State of Maryland 
prior to engaging in the enterprise of 
cultivating medical marijuana.  The registration process should 
focus on good manufacturing 
practices and security. If a grower 
is not registered, then its products 
may not be used in a program in 
the state, and they are subject to 
enforcement of state laws against 
marijuana cultivation. 
2  Patients who are participating in the program 
should be registered in a central database by 
the state or the oversight agency. Patients 
enrolled in the program will be provided an 
identification card that allows police to verify 
their participation in the program, but which 
does not compromise the confidentiality of 
other patients in the program.   Law enforcement should not have 
full access to the database 
(violation of patient 
confidentiality).  Law enforcement 
can use a unique patient identifier 
(provided on ID card) to receive 
verification of name, address, and 
current program status for the 
patient associated with that 
specific ID. 
3  There should be additional state penalties for 
gross misuse of a marijuana program for 
diversion purposes.  
4  Caregivers would be subject to a criminal 
background check and would be allowed to 
assist no more than five patients. Caregivers 
would be able to pick up the medical marijuana 
for patients and to assist patients with the act 
of administering marijuana or preparing it for 
administration.  
5  Any surplus raised by the medical marijuana 
oversight program could be apportioned for 
studies related to the medical marijuana 
program or to clinical trials, with any excess 
then going to the state’s general fund.  In other states, medical marijuana 
programs have generated 
substantial surpluses. For example, 
Michigan generated $4.4 million 
through its ID program in FY 2010 
and spent only $740,658 on the 
program in FY 2010.  
  Workgroup Members Signing on to Proposal 2  
  The following members of the workgroup signed on to Proposal 2:    
● Lynn Billing  
● Senator David Brinkley  
● Dario Broccolino  
● Philip Cogan  
● Delegate Kathleen Dumais  
● Deborah Miran  
● Delegate Dan Morhaim  
● Karen O’Keefe  
● Senator Jamie Raskin  
● Dr. Ryan Vandrey  
    Model Legislation to Implement Proposal 2 
SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, THAT SECTION(S) 5403(D), (E), AND (F), RESPECTIVELY, OF ARTICLE — CRIMINAL LAW OF THE ANNOTATED CODE OF MARYLAND BE RENUMBERED TO BE SECTION(S) 5-403(E), (F), AND (G), RESPECTIVELY.
SECTION 2. AND BE IT FURTHER ENACTED, THAT THE LAWS OF MARYLAND READ AS FOLLOWS:
ARTICLE — CRIMINAL LAW
SECTION 5-402
(D) (1)  A MATERIAL, COMPOUND, MIXTURE, OR PREPARATION THAT CONTAINS ANY OF THE  FOLLOWING HALLUCINOGENIC OR HALLUCINOGENIC-LIKE SUBSTANCES IS A SUBSTANCE LISTED IN  SCHEDULE I:
(I) BUFOTENINE;
(II) DIETHYLTRYPTAMINE;
(III) DIMETHYLTRYPTAMINE;
(IV) 4-METHYL-2, 5-DIMETHOXYAMPHETAMINE;
(V) IBOGAINE;
(VI) LYSERGIC ACID DIETHYLAMIDE;
[(VII) MARIJUANA;]
[(VIII)] (VII) MESCALINE;
[(IX)] (VIII) PEYOTE;
[(X)] (IX)  PSILOCYBIN;
[(XI)] (X)  PSILOCYN;
[(XII)] (XI)  TETRAHYDROCANNABINOL;
[(XIII)] (XII) THIOPHENE ANALOG OF PHENCYCLIDINE;
[(XIV)] (XIII)  2, 5-DIMETHOXYAMPHETAMINE;
[(XV)] (XIV) 4-BROMO-2, 5-DIMETHOXYAMPHETAMINE;
[(XVI)] (XV)  4-METHOXYAMPHETAMINE;
[(XVII)] (XVI)  3, 4-METHYLENEDIOXYAMPHETAMINE;
[(XVIII)] (XVII) 3, 4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA);
[(XIX)] (XVIII) 5-METHOXY-3, 4-METHYLENEDIOXYAMPHETAMINE;
3, 4, 5-TRIMETHOXYAMPHETAMINE;
[(XX)] (XIX)
N-METHYL-3-PIPERIDYL BENZILATE;
[(XXI)] (XX)
[(XXII)] (XXI)  N-ETHYL-3-PIPERIDYL BENZILATE;
[(XXIII)] (XXII) N-ETHYL-1-PHENYLCYCLOHEXYLAMINE;
[(XXIV)] (XXIII) 1-(1-PHENYLCYCLOHEXYL)-PYRROLIDINE;
[(XXV)] (XXIV)  1-(1-(2-THIENYL)-CYCLOHEXYL)-PIPERIDINE;
[(XXVI)] (XXV)  1-METHYL-4-PHENYL-4-PROPIONOXYPIPERIDINE (MPPP); AND [(XXVII)](XXVI) 1-(2-PHENYLETHYL)-4-PHENYL-4-ACETYLOXYPIPERIDINE (PEPAP).
5-403.
(D) A MATERIAL, COMPOUND, MIXTURE, OR PREPARATION THAT CONTAINS MARIJUANA IS A SUBSTANCE LISTED IN SCHEDULE II.
5-611.
(A) A PERSON WHO IS EMPLOYED BY A DISPENSING PHARMACY OR A DISPENSING CENTER  REGISTERED WITH THE MEDICAL MARIJUANA OVERSIGHT COMMISSION UNDER TITLE 13, SUBTITLE 30 OF THE HEALTH – GENERAL ARTICLE MAY NOT DISTRIBUTE OR DISPENSE
MARIJUANA EXCEPT TO A REGISTERED QUALIFYING PATIENT OR A REGISTERED PRIMARY  CAREGIVER.
(B) A PERSON WHO IS REGISTERED WITH THE COMMISSION AS A QUALIFYING PATIENT OR A PATIENT’S PRIMARY CAREGIVER UNDER TITLE 13, SUBTITLE 30 OF THE HEALTH – GENERAL ARTICLE MAY NOT DISTRIBUTE OR DISPENSE MARIJUANA TO ANOTHER PERSON WHO IS NOT A  REGISTERED QUALIFYING PATIENT.
(C) A REGISTERED ACADEMIC MEDICAL CENTER REGISTERED UNDER TITLE 13, SUBTITLE 30 OF THE HEALTH — GENERAL ARTICLE OR A CERTIFYING PHYSICIAN UNDER TITLE 13, SUBTITLE 30 OF THE HEALTH — GENERAL ARTICLE MAY NOT DISTRIBUTE OR DISPENSE
MARIJUANA TO ANOTHER PERSON WHO IS NOT A REGISTERED QUALIFYING PATIENT OR A  REGISTERED PRIMARY CAREGIVER.
(D) A PERSON WHO VIOLATES SUBSECTION (A) OR (B) OF THIS SECTION IS GUILTY OF A  FELONY AND ON CONVICTION IS SUBJECT TO IMPRISONMENT NOT EXCEEDING SEVEN (7) YEARS OR A FINE NOT EXCEEDING $7,000, OR BOTH.
ARTICLE—HEALTH—GENERAL SUBTITLE30.MEDICALMARIJUANA.
13-3001.
(A)IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.
(B) “BONA FIDE PHYSICIAN-PATIENT RELATIONSHIP” MEANS A RELATIONSHIP IN WHICH  THE PHYSICIAN HAS ONGOING RESPONSIBILITY FOR THE ASSESSMENT, CARE, AND TREATMENT  OF A PATIENT’S MEDICAL CONDITION.
(C) “CERTIFYING PHYSICIAN” MEANS AN INDIVIDUAL LICENSED BY THE STATE BOARD OF PHYSICIANS UNDER TITLE 14 OF THE HEALTH OCCUPATIONS ARTICLE TO PRACTICE MEDICINE  WHO:
(1) HAS COMPLETED A TRAINING COURSE DESIGNED BY THE MEDICAL MARIJUANA  OVERSIGHT COMMISSION AND HAS BEEN APPROVED BY THE COMMISSION; OR
(2) HAS COMPLETED TRAINING WITH A REGISTERED ACADEMIC MEDICAL CENTER AND  IS CERTIFYING PATIENTS UNDER THE AUSPICESOF A REGISTERED ACADEMIC MEDICAL  CENTER.
(D) “DISPENSING CENTER” MEANS AN ENTITY REGISTERED UNDER THIS SUBTITLE THAT ACQUIRES, POSSESSES, DELIVERS, TRANSFERS, TRANSPORTS, SUPPLIES, SELLS, OR DISPENSES  MARIJUANA OR RELATED SUPPLIES AND EDUCATION MATERIALS.
(E) “DISPENSING PHARMACY” MEANS A PHARMACY REGISTERED UNDER THIS SUBTITLE  THAT ACQUIRES, POSSESSES, DELIVERS, TRANSFERS, TRANSPORTS, SELLS, SUPPLIES, OR DISPENSES MARIJUANA OR RELATED SUPPLIES AND EDUCATIONAL MATERIALS.
(F) “MARIJUANA” HAS THE MEANING STATED IN § 5-101 OF THE CRIMINAL LAW ARTICLE.
(G) “MEDICAL MARIJUANA OVERSIGHT COMMISSION” OR “COMMISSION” MEANS AN
INDEPENDENT COMMISSION APPOINTED BY THE GOVERNOR TO REGISTER AND REGULATE ACADEMIC MEDICAL CENTERS, CERTIFYING PHYSICIANS, GROWERS, DISPENSING CENTERS, AND  DISPENSING PHARMACIES.
(H) “MEDICAL USE” MEANS THE ACQUISITION, POSSESSION, CULTIVATION, MANUFACTURE, USE, DELIVERY, SALE, TRANSFER, OR TRANSPORTATION OF MARIJUANA OR
PARAPHERNALIA RELATING TO THE ADMINISTRATION OF MARIJUANA TO TREAT OR ALLEVIATE  A REGISTERED PATIENT’S CONDITION OR SYMPTOMS.
(1) (1) “PRIMARY CAREGIVER” MEANS A RESIDENT OF THE STATE WHO:
(I) IS AT LEAST 18 YEARS OLD;
(II) HAS AGREED TO ASSIST WITH NO MORE THAN FIVE QUALIFYING PATIENTS’ MEDICAL USE OF MARIJUANA;
(III) HAS BEEN DESIGNATED AS PRIMARY CAREGIVER ON THE QUALIFYING PATIENT’S
APPLICATION OR RENEWAL FOR A REGISTRY IDENTIFICATION CARD FOR THE PRIMARY CAREGIVER; AND
(IV)HAS SATISFIED THE CRIMINALHISTORY RECORDS CHECK REQUIRED UNDER §133008 OF THISSUBTITLE.
(2)“PRIMARY CAREGIVER” DOES NOT INCLUDE THE QUALIFYING PATIENT’S CERTIFYING  PHYSICIAN.
(J)“QUALIFYING PATIENT”MEANS A RESIDENT OF THE STATE WHO:
(1) IS ATLEAST 18 YEARS OLD, UNLESS THE COMMISSION GRANTS AN EXCEPTION AT THE RECOMMENDATIONOF THE PATIENT’S CERTIFYING PHYSICIAN; AND
(2) HAS BEEN PROVIDED WITH WRITTEN CERTIFICATION BYA CERTIFYING PHYSICIAN  PURSUANT TO A BONA FIDE PHYSICIAN-PATIENT RELATIONSHIP; OR
(3) IS ENROLLED IN A RESEARCH PROGRAM WITHA REGISTERED ACADEMIC MEDICAL  CENTER.
(K)“REGISTERED GROWER” MEANS AN ENTITY THAT:
(1) IS REGISTERED BY THE COMMISSION UNDER THIS SUBTITLE TO BEEXEMPT FROM STATE AND LOCAL PENALTIES FOR CULTIVATINGMARIJUANA IN ACCORDANCE WITHTHIS ACT;
AND
(2) IS EXEMPT FROM STATE AND LOCAL PENALTIES FORTRANSFERRING MARIJUANA  CULTIVATED BY THE ENTITY TO A DISPENSING PHARMACY ORTO A DISPENSING CENTERFOR A  FEE.
(L)(1)“REGISTERED ACADEMIC MEDICAL CENTER” MEANS A PROGRAM APPROVEDBY  THE COMMISSION TO CONDUCT RESEARCHREGARDING THE MEDICAL USE OF MARIJUANA BY HUMANS.
(2)A REGISTERED ACADEMIC MEDICAL CENTER MUST:
(I)OPERATE A MEDICALRESIDENCY PROGRAM FORPHYSICIANS; AND
(II)CONDUCT RESEARCHTHAT ISOVERSEEN BY THE FEDERAL DEPARTMENT OF  HEALTH AND HUMAN SERVICES AND THAT INVOLVES HUMAN SUBJECTS.
(M)“REGISTRY IDENTIFICATION CARD” MEANS A DOCUMENT ISSUED BYTHE  COMMISSION THAT IDENTIFIES AN INDIVIDUAL AS A QUALIFYING PATIENT OR PRIMARY  CAREGIVER.
(N)(1)“USABLE MARIJUANA”MEANS THEDRIED LEAVES AND FLOWERSOFMARIJUANA  AND ANY MIXTURE OR PREPARATION OFTHE DRIED LEAVES AND FLOWERS.
(2)“USABLE MARIJUANA” DOES NOT INCLUDE THE SEEDS, STALKS, OR ROOTS OF THE
PLANT.
(O)“WRITTEN CERTIFICATION” MEANS A CERTIFICATION ISSUED BYA CERTIFYING PHYSICIAN TO A QUALIFYING PATIENT WITH WHOM THE PHYSICIAN HAS A BONA FIDE PHYSICIAN-PATIENT RELATIONSHIPTHATINCLUDES A STATEMENTCERTIFYING THAT:
(1)IN THE PHYSICIAN’S PROFESSIONALOPINION, AFTER HAVING COMPLETED A FULL ASSESSMENT OF THE PATIENT’S MEDICALHISTORY AND CURRENT MEDICAL CONDITION, THE
PATIENTHAS A CONDITION WHICH MEETS THE INCLUSION CRITERIA ANDDOES NOT MEETTHE  EXCLUSIONCRITERIA OFTHE CERTIFYING PHYSICIAN’S APPLICATION, AND FOR WHICH:
(I)RECOGNIZED DRUGS OR TREATMENT WOULDNOT BE EFFECTIVE; OR
(II)OTHER TREATMENTOPTIONS HAVEMORESERIOUS SIDE EFFECTSOR A GREATER  RISK OFADDICTION; AND
(III)THE POTENTIAL BENEFITS OFTHE MEDICAL USE OF MARIJUANA WOULDLIKELY OUTWEIGH THE HEALTH RISKS FOR THE PATIENT.
13-3002.
(A)THERE IS AMEDICALMARIJUANA OVERSIGHTCOMMISSION.
(B)THE COMMISSION IS AN INDEPENDENT COMMISSION THAT FUNCTIONS WITHIN THE  DEPARTMENT OFHEALTH ANDMENTAL HYGIENE.
(C)(1)THE COMMISSION CONSISTSOF15 MEMBERS,WHICH SHALL INCLUDE BROADBASED REPRESENTATIVES OF ALLSTAKEHOLDERS.
 (2)THE COMMISSION SHALL INCLUDE:
(I) TWO MEMBERS OF THE SENATE OF MARYLAND,APPOINTEDBY THE PRESIDENT OF  THE SENATE; 
(II) TWO MEMBERS OF THE HOUSE OFDELEGATES, APPOINTED BY THESPEAKER OF THE HOUSE; 
(III) THESECRETARY OFHEALTH AND MENTAL HYGIENE, ORTHESECRETARY’S  DESIGNEE, WHO SHALL SERVE EXOFFICIO; AND
 (IV)10 MEMBERS, APPOINTED BY THE GOVERNOR, INCLUDING THE FOLLOWING  MEMBERS: 
 (1) ONE MEMBER OFTHE PUBLIC WHO SUPPORTS THE USE OF MARIJUANA FOR  MEDICAL PURPOSESAND WHO ISOR WAS APATIENT WHOFOUND RELIEF FROM MEDICAL MARIJUANA; 
(2) TWO PHYSICIANSLICENSED IN THESTATE; 
(3) ONE NURSE LICENSED IN THE STATE; 
(4) ONE PHARMACIST LICENSED INTHE STATE: 
(5) ONE SCIENTIST WHO HAS CONDUCTED GRANT-FUNDED RESEARCH; 
(6) TWO MEMBERS WITHEXPERIENCE IN LAW ENFORCEMENT; AND
 (7) AN ATTORNEY WHO IS KNOWLEDGEABLE ABOUT MEDICAL MARIJUANA LAWS IN THE  UNITED STATES. 
(D)THE TERM OF A MEMBER ISFOUR YEARS.
(E)THE TERMS OFTHE APPOINTED MEMBERS ARE STAGGERED AS REQUIRED BY THE TERMSPROVIDED FOR MEMBERS ONOCTOBER1,2012.
(F)AMEMBER WHO SERVES TWO CONSECUTIVE FULL FOUR-YEAR TERMS MAY NOT BE REAPPOINTED FOR FOUR YEARS AFTER COMPLETIONOFTHOSE TERMS. 
(G)A MEMBER WHO ISAPPOINTED AFTER A TERM HAS BEGUN SERVES ONLY FORTHE REST OF THETERM AND UNTILA SUCCESSOR ISAPPOINTED AND QUALIFIES.
(H)ANNUALLY, FROM AMONG THE MEMBERS OFTHE COMMISSION:  (1)THE GOVERNOR SHALL APPOINT A CHAIRMAN; AND (2)THE CHAIRMAN SHALL APPOINT A VICE CHAIRMAN.  (I)A MEMBER OFTHE COMMISSION:
(1)MAY NOT RECEIVE COMPENSATION AS A MEMBER OFTHECOMMISSION; BUT
(2)IS ENTITLED TO REIMBURSEMENTFOR EXPENSES UNDER THE STANDARD STATE TRAVEL REGULATIONS, AS PROVIDED IN THESTATE BUDGET.
(J)(1)THE COMMISSION MAY EMPLOY A STAFF, INCLUDING CONTRACTUAL STAFF, IN ACCORDANCE WITH THE STATE BUDGET OR FUNDED DIRECTLY BY APPLICATION AND REGISTRATION FEES AND GRANTS TO THE COMMISSION.
(2)THE COMMISSION, IN CONSULTATION WITHTHE SECRETARY, SHALL DETERMINE THE  APPROPRIATE JOB CLASSIFICATIONS AND GRADES FOR ALL STAFF. 
(K)THECOMMISSION SHALL CONSULT WITH EXPERTS IN PERFORMING ITS DUTIES.
(L) THE COMMISSION SHALL MEETAT LEAST SIXTIMESAYEAR, AT THETIMESAND PLACESTHAT IT DETERMINES.
13-3003.
(A)IN ADDITION TO THEPOWERS SET FORTH ELSEWHERE IN THIS SUBTITLE, THE  COMMISSION MAY:
(1)ADOPT RULES AND REGULATIONS TOCARRY OUT THE PROVISIONSOF THIS  SUBTITLE;
(2)CREATE SUBCOMMITTEES FROM AMONG ITS MEMBERS;
(3)APPOINT ADVISORY COMMISSIONS, WHICHMAY INCLUDE INDIVIDUALS AND  REPRESENTATIVES OF INTERESTED PUBLIC ORPRIVATE ORGANIZATIONS;
(4)APPLY FOR AND ACCEPTANY FUNDS, PROPERTY, OR SERVICES FROM ANY PERSON OR GOVERNMENT AGENCY;
(5)MAKE AGREEMENTS WITHA GRANTOR OR PAYER OFFUNDS, PROPERTY, OR SERVICES;
(6)PUBLISH AND DISSEMINATE ANY INFORMATION THATRELATES TO THE MEDICAL USE  OF MARIJUANA AND RELATED RESEARCH; AND
(7)SUBJECT TO THE LIMITATIONS OF THIS SUBTITLE,EXERCISE ANY OTHER POWER  THAT IS REASONABLY NECESSARY TO CARRY OUTTHE PURPOSES OFTHIS SUBTITLE.
(B)IN ADDITION TO THE DUTIES SET FORTH ELSEWHERE INTHIS SUBTITLE, THE COMMISSION SHALL:
(1)ADOPT RULES AND REGULATIONS THAT RELATETO ITS MEETINGS, MINUTES, AND  TRANSACTIONS;
(2)KEEP MINUTES OFEACH MEETING;
(3)PREPARE ANNUALLYA BUDGETPROPOSAL THAT INCLUDES THE ESTIMATED INCOME  OFTHE COMMISSION AND PROPOSED EXPENSES FOR ITS ADMINISTRATION AND  OPERATION; AND
(4)PREPAREFROMTHE INFORMATION FILED WITH THECOMMISSION ANYSUMMARY, COMPILATION, OR OTHERSUPPLEMENTARYREPORT THAT WILL ADVANCETHEPURPOSES OF  THIS SUBTITLE.
(C) (1)THE COMMISSION MAY CONTRACT WITHA QUALIFIED, INDEPENDENT THIRD PARTY FOR ANYSERVICE NECESSARY TOCARRY OUT THE POWERS ANDDUTIES OF THE  COMMISSION.
(2)UNLESS PERMISSION IS GRANTED SPECIFICALLY BY THECOMMISSION, A THIRD  PARTY HIRED BY THE COMMISSIONMAY NOT RELEASE, PUBLISH, OR OTHERWISE USE ANY  INFORMATION TO WHICHTHE THIRD PARTY HAS ACCESS UNDER ITS CONTRACT.
(D)(1)ON OR BEFORE SEPTEMBER 1,2012, THECOMMISSION SHALL ADOPT  REGULATIONS TOIMPLEMENT THISSUBTITLE.
(2)THE COMMISSION MAY SUSPEND OR REVOKE THE REGISTRATIONS OFACADEMIC MEDICAL CENTERS, DISPENSING CENTERS, DISPENSING PHARMACIES, PHYSICIANS, AND
REGISTERED GROWERSTHAT COMMIT ANY VIOLATIONS OFTHIS ACT ORREGULATIONS ISSUED
PURSUANT TO THE ACT.
(E)DISPENSING CENTERS, REGISTERED GROWERS, AND REGISTERED PHARMACIESARE  SUBJECT TO INSPECTION BY THE COMMISSION.
(F)THECOMMISSION SHALL ADVANCE THE DEVELOPMENT OF SCIENTIFIC INFORMATION RELATED TO THE MEDICAL USE OF MARIJUANA.
(G)COMMISSION REGULATIONS SHALL NOT REQUIRE REGISTERED ACADEMIC MEDICAL CENTERS OR PHYSICIANS TO:
(I)DESIGNATE DISPENSING CENTERS OR DISPENSING PHARMACIESFOR PATIENTS; (II)POSSESS, CULTIVATE, OR DISTRIBUTE MARIJUANA; OR
(III)HAVEANY CONTROL OVERTHE POSSESSION, CULTIVATION, OR DISTRIBUTION OF MARIJUANA.
13-3004.
(A) THE COMMISSION SHALL CONSULT WITH EXPERTS, INCLUDING ACADEMICS AND MEDICAL PROFESSIONALS, AND ESTABLISH A TRAINING PROGRAM FOR PHYSICIANS WISHING TO BECOME CERTIFYING PHYSICIANS.
(B) THE COMMISSION SHALL SET A REASONABLE FEE FOR PROCESSING PHYSICIAN  APPLICATIONS AND FOR THE TRAINING PROGRAM FOR PHYSICIANS.
(C) (1) THE COMMISSION SHALL APPROVE CERTIFYING PHYSICIANS THAT MEET THE REQUIREMENTS OF THIS SUBTITLE, COMPLETE THE TRAINING PROGRAM, AND SUBMIT  SATISFACTORY APPLICATION MATERIALS.
(2) EACH PHYSICIAN CERTIFICATION MUST BE RENEWED ANNUALLY.
(D) A PHYSICIAN’S PROPOSAL MUST INCLUDE:
(1) THE CRITERIA BY WHICH PATIENTS WILL BE INCLUDED IN THE PROGRAM, INCLUDING  QUALIFYING MEDICAL CONDITIONS;
(2) THE CRITERIA BY WHICH THE PHYSICIAN WILL EXCLUDE PATIENTS FROM THE PROGRAM;
(3) THE PHYSICIAN’S PLAN FOR SCREENING PATIENTS FOR DEPENDENCE, BOTH BEFORE AND AFTER THE QUALIFYING PATIENT IS ISSUED A WRITTEN CERTIFICATION; AND
(4) THE PHYSICIAN’S PLAN FOR THE ONGOING ASSESSMENT AND FOLLOW-UP CARE FOR  PATIENTS AND THE COLLECTION OF DATA.
(E) PROVIDED TREATING A GIVEN MEDICAL CONDITIONS FALLS WITHIN A PHYSICIAN’S  CLINICAL PRACTICE AREA, THE COMMISSION IS ENCOURAGED TO APPROVE APPLICATIONS FOR THE FOLLOWING MEDICAL CONDITIONS:
(1)A CHRONIC OR DEBILITATING DISEASE OR MEDICAL CONDITION THAT RESULTEDIN  THE PATIENT BEING ADMITTED INTO HOSPICE OR RECEIVING PALLIATIVE CARE; AND
(2)A CHRONIC OR DEBILITATING DISEASE ORMEDICAL CONDITION OR THE TREATMENT OF
A CHRONIC OR DEBILITATING DISEASE OR MEDICALCONDITION THAT PRODUCES ONE OR MORE  OF THE FOLLOWING: CACHEXIA, ANOREXIA,OR WASTING SYNDROME, SEVERE OR CHRONIC  PAIN, SEVERE NAUSEA, SEIZURES, OR SEVERE AND PERSISTENT MUSCLE SPASMS.
(3)THE COMMISSION MAY APPROVE APPLICATIONSTHAT INCLUDEANY OTHER CONDITION THAT IS SEVERE AND RESISTANTTOCONVENTIONAL MEDICINE PROVIDED THAT:
(I) FAILURE OF APPROVED MEDICATIONS TO PROVIDE RELIEF HAS BEEN  DOCUMENTED; AND
(II) THE SYMPTOMS CAN REASONABLY BE EXPECTED TO BE RELIEVED BY THE MEDICAL USE OF MARIJUANA.
(F) CERTIFYING PHYSICIANS SHALL BE PROTECTED FROM CIVIL AND CRIMINAL PENALTIES UNDER STATE AND LOCAL LAWS FOR THE ACTIVITIES ALLOWED BY THIS SUBTITLE, INCLUDING ISSUING WRITTEN CERTIFICATIONS AND COLLECTING AND ANALYZING DATA.
(G) (1) EACH YEAR, NO LATER THAN 60 DAYS BEFORE ITS REGISTRATION EXPIRES, EACH  CERTIFYING PHYSICIAN SHALL SUBMIT AN ANNUAL REPORT TO THE COMMISSION.
(2) ANNUAL REPORTS SHOULD INCLUDE INFORMATION ON THE NUMBER OF PATIENTS  SERVED, THE COUNTY OR COUNTIES OF RESIDENCE, THE MEDICAL CONDITION(S) FOR WHICH  MEDICAL MARIJUANA WAS RECOMMENDED, AND A SUMMARY OF CLINICAL OUTCOMES SHOULD  BE PROVIDED, INCLUDING A SUMMARY OF ADVERSE EVENTS AND A SUMMARY OF ANY CASES OF SUSPECTED DIVERSION.
(3) ANNUAL REPORTS MAY NOT INCLUDE ANY PERSONALLY IDENTIFIABLE INFORMATION  ABOUT PATIENTS.
(H) CERTIFYING PHYSICIANS MAY APPLY FOR RENEWED REGISTRATIONS ANNUALLY. THE COMMISSION SHALL GRANT OR DENY A REGISTRATION BASED ON THE CERTIFYING PHYSICIAN’S  PERFORMANCE, INCLUDING WHETHER HE OR SHE IS PROVIDING CERTIFICATIONS FOR MEDICAL  CONDITIONS WITHIN HIS OR HER PRACTICE AREA.
13-3005
(A) THE COMMISSION SHALL SET A REASONABLE FEE FOR PROCESSING ACADEMIC MEDICAL CENTER APPLICATIONS.
(B) (1) THE COMMISSION SHALL APPROVE ACADEMIC MEDICAL CENTERS THAT MEET THE  REQUIREMENTS OF THIS SUBTITLE AND SUBMIT SATISFACTORY PROPOSALS.
(2) EACH REGISTERED ACADEMIC MEDICAL CENTER REGISTRATION EXPIRES AFTER ONE  YEAR, UNLESS IT IS RENEWED.
(C)AN ACADEMIC MEDICAL CENTER’S PROPOSAL MUST INCLUDE:
(1)A LIST OF MEDICALPROVIDERS WHO INTEND TOPARTICIPATEINTHE PROGRAM, AND THEIR QUALIFICATIONS FOR PARTICIPATION, INCLUDING THEIR PROFESSIONAL CREDENTIALS  AND TRAINING SPECIFIC TOTHE MEDICAL USE OF MARIJUANA;
(2)THE CRITERIA BY WHICH THE ACADEMIC MEDICAL CENTERS WILLINCLUDE PATIENTS IN THE PROGRAM, INCLUDING QUALIFYING MEDICAL CONDITIONS;
(3)THE CRITERIA BY WHICH THEACADEMIC MEDICAL CENTERS WILLEXCLUDEPATIENTS FROM THE PROGRAM;
(4)THE ACADEMIC MEDICAL CENTER’S PLAN FOR SCREENING PATIENTSFOR  DEPENDENCE, BOTH BEFORE AND AFTER THE QUALIFYING PATIENT IS ISSUED A WRITTEN  CERTIFICATION;
(5)THE ACADEMIC MEDICAL CENTER’S PLAN FOR THE ONGOING ASSESSMENT AND  FOLLOW-UP CARE FOR PATIENTS AND THE COLLECTION ANDANALYZING OFDATA;
(6)ANY CLINICALTRIALS OR ADDITIONAL RESEARCH RELATED TO MEDICAL MARIJUANA  THATTHE ACADEMIC MEDICAL CENTER INTENDS TO ENGAGE IN; AND
(7)A LETTER OF APPROVALFROM AN INSTITUTIONAL REVIEW BOARD FOR ALLPROPOSED RESEARCH ACTIVITIES.
(D)THECOMMISSION IS ENCOURAGED TO APPROVE OTHERWISE SATISFACTORY APPLICATIONS THAT INCLUDE ANY OR ALL OFTHE FOLLOWING MEDICALCONDITIONS:
(1) A CHRONIC OR DEBILITATING DISEASE OR MEDICAL CONDITION THAT RESULTED IN  THE PATIENT BEING ADMITTED INTO HOSPICE OR RECEIVING PALLIATIVE CARE; AND
(2) A CHRONIC OR DEBILITATING DISEASE OR MEDICAL CONDITION OR THE TREATMENT
OF A CHRONIC OR DEBILITATING DISEASE OR MEDICAL CONDITION THAT PRODUCES ONE OR  MORE OF THE FOLLOWING: CACHEXIA, ANOREXIA, OR WASTING SYNDROME, SEVERE OR  CHRONIC PAIN, SEVERE NAUSEA, SEIZURES, OR SEVERE AND PERSISTENT MUSCLE SPASMS.
(E) THE COMMISSION MAY APPROVE APPLICATIONS THAT INCLUDE ANY OTHER CONDITION THAT IS SEVERE AND RESISTANT TO CONVENTIONAL MEDICINE PROVIDED THAT:
(1) FAILURE OF APPROVED MEDICATIONS TO PROVIDE RELIEF HAS BEEN  DOCUMENTED; AND
(2) THE SYMPTOMS CAN REASONABLY BE EXPECTED TO BE RELIEVED BY THE MEDICAL USE OF MARIJUANA.
(F) A REGISTERED ACADEMIC MEDICAL CENTER, PHYSICIANS WHO ARE PART OF A  REGISTERED ACADEMIC MEDICAL CENTER’S PROGRAM, AND REGISTERED ACADEMIC MEDICAL  CENTERS’ STAFF SHALL BE PROTECTED FROM CIVIL AND CRIMINAL PENALTIES UNDER STATE AND LOCAL LAWS FOR THE ACTIVITIES ALLOWED BY THIS SUBTITLE, INCLUDING CONDUCTING
RESEARCH INVOLVING MEDICAL MARIJUANA AND CERTIFYING PATIENTS TO PARTICIPATE IN  THE PROGRAM.
(G)(1)EACH YEAR,NO LATER THAN60 DAYS BEFORE ITS REGISTRATION EXPIRES, THE
REGISTERED ACADEMIC MEDICAL CENTER SHALLSUBMIT AN ANNUALREPORT TO THE  COMMISSION.
(2)ANNUALREPORTS SHOULD INCLUDE INFORMATION ON THE NUMBER OFPATIENTS  SERVED,THE COUNTY OR COUNTIES OFRESIDENCE,THE MEDICAL CONDITION(S) FOR WHICH  MEDICAL MARIJUANA WAS RECOMMENDED, AND A SUMMARY OF CLINICAL OUTCOMES SHOULD  BE PROVIDED FOR EACH INDIVIDUAL PATIENT, INCLUDING ASUMMARY OFADVERSE EVENTS, A  SUMMARY OFANY CASES OF SUSPECTED DIVERSION ATTHE LEVEL OF PATIENT, PROGRAM, OR  DISPENSING CENTER,AND PROGRESS REPORTS ON RESEARCH STUDIES CONDUCTED UNDER  THE MEDICAL MARIJUANA PROGRAM.
(3)ACADEMIC MEDICAL CENTER REPORTS MAYNOT INCLUDE ANYPERSONALLY IDENTIFIABLE INFORMATIONABOUT PATIENTS.
(4)THE REGISTERED ACADEMIC MEDICAL CENTER SHALL PREPARE A LAY SUMMARY OF THE REPORT THATISPUBLICLY AVAILABLE.
(H)ACADEMIC MEDICAL CENTERSMAY APPLY FOR RENEWED REGISTRATIONSANNUALLY. THE COMMISSION SHALL GRANT ORDENY A REGISTRATION BASEDON THE REGISTERED  ACADEMIC MEDICAL CENTER’S PERFORMANCE,INCLUDING WHETHER IT IS PROVIDING
APPROPRIATE TRAINING AND OVERSIGHTFORCERTIFYING PHYSICIANS AND COLLECTINGAND  ANALYZING DATA.
13-3006.
(A)THECOMMISSION SHALL ISSUE A REQUESTFOR APPLICATIONSFORREGISTERED GROWERS THAT WILL BE EXEMPTFROM CRIMINAL PENALTIES UNDER STATE LAW.
(B)(1)THE COMMISSION SHALL REQUIRE AN APPLICANT FOR A REGISTRATION TO  PROVIDE THE FOLLOWING INFORMATION TO THECOMMISSION:
(I)THE NAME OFTHE INDIVIDUAL WHO ISRESPONSIBLE FOR OPERATING THE  CULTIVATION FACILITY;
(II)THELOCATION OFTHE PROPOSED CULTIVATION FACILITY OR CULTIVATION  FACILITIES;
(III)THESECURITY MEASURESTHAT WILL BE FOLLOWED BY THE REGISTERED GROWER  IN CULTIVATING, STORING, AND TRANSPORTING MARIJUANA;
(IV)THE METHOD BY WHICH THE REGISTEREDGROWER WILL ACCOUNTFOR THE AMOUNT
OF MARIJUANA CULTIVATED AND TRANSFERRED TO DISPENSING CENTERS AND DISPENSING  PHARMACIES;
(V)THE TRAINING THAT WILL BE PROVIDEDTO EMPLOYEESTO PREVENT DIVERSION; (VI)HOW THE PROGRAM WILLADDRESS VIOLATIONS OF THE DIVERSION POLICY; AND (VII)ANY OTHER INFORMATION THATTHECOMMISSION CONSIDERS NECESSARY.
(2) THE COMMISSION SHALL SELECT THE FEWEST NUMBER OF REGISTERED GROWERS  UNDER THIS SECTION AS IS REASONABLE.
(3) REGISTRATIONS EXPIRE ONE YEAR AFTER DATE OF ISSUANCE. REGISTRATIONS MAY  BE RENEWED ANNUALLY.
(C) REGISTERED GROWERS WILL BE EXEMPT FROM STATE AND LOCAL PENALTIES FOR  CULTIVATING MARIJUANA FOR MEDICAL USE IN ACCORDANCE WITH THIS ACT. A REGISTERED  GROWER SHALL:
(1) BE PROTECTED FROM CIVIL AND CRIMINAL PENALTIES UNDER STATE AND LOCAL LAWS FOR POSSESSING AND CULTIVATING MARIJUANA IN ACCORDANCE WITH THIS SUBTITLE;
(2) BE PROTECTED FROM CIVIL AND CRIMINAL PENALTIES UNDER STATE AND LOCAL LAWS FOR SELLING, TRANSPORTING, OR TRANSFERRING MARIJUANA TO DISPENSING CENTERS, DISPENSING PHARMACIES, AND REGISTERED ACADEMIC MEDICAL CENTERS IN ACCORDANCE  WITH THIS SUBTITLE;
(3) MEET CERTAIN SECURITY AND SAFETY STANDARDS THAT MAY BE VERIFIED BY THE COMMISSION;
(4) SUBMIT TO PHARMACOLOGICAL TESTING OF THE MARIJUANA CONDUCTED BY THE  REGISTERED GROWER OR A PRIVATE ENTITY TO ENSURE:
(I) THAT THE MARIJUANA CAN BE ACCURATELY LABELED BASED ON ITS POTENCY AND  STRAIN; AND
(II) THAT THERE IS NO ADULTERATION OR CONTAMINATION OF THE MARIJUANA.
(5) CONDUCT A CRIMINAL HISTORY RECORDS CHECK ON ANY EMPLOYEE OF THE  REGISTERED GROWER AS PROVIDED FOR IN THIS SUBTITLE, UNLESS THE REGISTERED GROWER IS ALSO A REGISTERED ACADEMIC MEDICAL CENTER.
(IV) A REGISTERED GROWER MAY NOT:
(1) HOLD ANY OTHER REGISTRATION ISSUED UNDER THIS SUBTITLE UNLESS THE REGISTERED GROWER IS ALSO A REGISTERED ACADEMIC MEDICAL CENTER; OR
(2) BE A CERTIFYING PHYSICIAN.
(E) (1) UNLESS A REGISTERED GROWER IS ALSO A REGISTERED ACADEMIC MEDICAL  CENTER, AN INDIVIDUAL WHO HAS BEEN CONVICTED OF SALE OF A CONTROLLED DANGEROUS  SUBSTANCE MAY NOT BE AN EMPLOYEE OF A REGISTERED GROWER, UNLESS THE CONVICTION
WAS FOR A VIOLATION OF FEDERAL LAW RELATING TO SALE OF MARIJUANA FOR CONDUCT  THAT IS LEGAL UNDER THIS SUBTITLE.
(2) UNLESS A REGISTERED GROWER IS ALSO A REGISTERED ACADEMIC MEDICAL CENTER, AN INDIVIDUAL WHO HAS BEEN CONVICTED OF A FELONY MAY NOT BE AN EMPLOYEE OF A REGISTERED GROWER.
(F)THE COMMISSION,AFTER CONSULTING WITHTHEDEPARTMENT OFAGRICULTURE  AND STATEPOLICE, SHALL ADOPT REGULATIONS TOBEFOLLOWEDBY A REGISTEREDGROWER, INCLUDING:
(1)THE SECURITYFEATURESTO BE REQUIRED ON THE PREMISES, WHICH SHALL INCLUDE A REQUIREMENT FOR SECURITY24HOURS PER DAY, SEVEN (7) DAYS PER WEEK AND A  PROHIBITION ON CULTIVATING MARIJUANA OUTDOORS;
(2)THE SECURITYFEATURESTO BE REQUIRED IN TRANSPORT TO ANENTITY THAT  OBTAINS A REGISTRATION TO DISPENSE MARIJUANA;
(3)LABELING REQUIREMENTS, WHICH SHALL INCLUDETHE WEIGHT OF MARIJUANA IN EACHPACKAGE AND THE FOLLOWING TEXTOR TEXT SUBSTANTIALLY SIMILAR TOIT: “WARNING:FOR QUALIFYING PATIENTS’ MEDICAL USE ONLY.KEEP AWAY FROM CHILDREN. DO NOT OPERATE MACHINERY OR DRIVE WHILE UNDER THE INFLUENCE OF MARIJUANA.”
(4)THELOCATION OF REGISTEREDGROWERS; AND
(5)REGULATIONS TO ENSURE THATREGISTEREDGROWERS ACCURATELY TRACK THE
AMOUNT OF MARIJUANA PRODUCED AND DISPENSED AND TO WHOM THE MARIJUANA IS  DISPENSED.
(G)(1)THE COMMISSION MAY ESTABLISHAFEE FOR RENEWAL APPLICATIONS AND  RENEWED REGISTRATIONS FOR REGISTERED GROWERS.
(2)THE COMMISSION SHALL GRANT OR DENYA RENEWAL BASED ON THE REGISTERED  GROWER’S PERFORMANCE, INCLUDING WHETHER ITHAS FOLLOWED REGULATIONS, INCLUDING  BY IMPLEMENTING APPROPRIATE PROCEDURESFOR SECURITY AND NON-DIVERSION.
13-3007.
(A) (1) (I) THE COMMISSION SHALL ESTABLISH A REGISTRATION PROGRAM TO REGISTER  ENTITIES THAT ARE EXEMPT FROM STATE AND LOCAL PENALTIES FOR DISTRIBUTING MARIJUANA FOR MEDICAL PURPOSES.
(II) THE COMMISSION SHALL CHARGE A REASONABLE FEE FOR AN APPLICATION TO BE EXEMPT FROM STATE AND LOCAL PENALTIES FOR DISTRIBUTING MARIJUANA FOR MEDICAL  PURPOSES.
(III) THE COMMISSION SHALL CHARGE A REASONABLE FEE FOR THE ISSUANCE OF A  REGISTRATION UNDER THIS SECTION.
(2) THE COMMISSION SHALL REQUIRE AN APPLICANT FOR A DISPENSING CENTER OR
DISPENSING PHARMACY REGISTRATION TO PROVIDE THE FOLLOWING INFORMATION TO THE COMMISSION:
(I) AN APPLICATION FEE;
(II) THE NAME OF THE INDIVIDUAL WHO IS RESPONSIBLE FOR OPERATING THE  DISPENSING PHARMACY OR DISPENSING CENTER;
(III)THE LOCATION OF THE PHARMACY OR DISPENSING CENTER;
(IV)THE SECURITY MEASURESTHAT WILL BEFOLLOWED BYTHEPHARMACY OR DISPENSING CENTER IN RECEIVING, STORING, AND DISPENSING MARIJUANA;
(V)THE METHOD BY WHICHTHE PHARMACY ORDISPENSING CENTER WILL ACCOUNTFOR  THE AMOUNT OFMARIJUANA RECEIVED AND DISPENSED;
(VI)THETRAINING THAT WILL BE PROVIDEDTO EMPLOYEESTO PREVENT DIVERSION; (VII)HOW THE PROGRAM WILLADDRESS VIOLATIONS OF THE DIVERSION POLICY; AND (VIII)ANY OTHER INFORMATION THAT THE COMMISSION CONSIDERS NECESSARY.
(3)THE FOLLOWING ENTITIES MAY REGISTERWITH THE COMMISSION TO BE EXEMPT FROMSTATE AND LOCAL PENALTIES FOR DISTRIBUTING MARIJUANA FOR MEDICAL PURPOSES:
(I)A PHARMACY THAT HOLDSA PHARMACYREGISTRATION ISSUED BY THEBOARD OF PHARMACY; OR
(II)A DISPENSING CENTER AS PROVIDED FOR IN THIS SECTION.
(4)A REGISTERED ACADEMIC MEDICAL CENTER WISHING TO DISPENSETO PATIENTSIS  NOTREQUIRED TO ALSO BE REGISTERED AS A DISPENSING CENTER.HOWEVER, IF A  REGISTERED ACADEMIC MEDICAL CENTER WISHES TO DISPENSE MARIJUANA TO PATIENTS, ITS  APPLICATION TO OPERATE AS A REGISTERED ACADEMIC MEDICAL CENTER MUST INCLUDE:
(I)ASUMMARY OFTHE TRAINING THAT WILL BE PROVIDED TO EMPLOYEES AND TO PATIENTS TOPREVENT DIVERSION;
(II)A DESCRIPTION OFTHE MATERIALS THAT WILL BE PROVIDEDTO PATIENTS TO ENSURE INFORMED CONSENT; AND
(III)ADESCRIPTION OF HOW THE PROGRAM WILL ADDRESS VIOLATIONS OF THE  DIVERSION POLICY.
(B)(1)AN ENTITY SEEKING TO OPERATE AS A DISPENSING CENTER SHALL PERFORM A  CRIMINALHISTORY RECORDS CHECK ON EACH EMPLOYEE.
(2)THIS REQUIREMENT DOES NOT APPLY TO DISPENSING PHARMACIES OR REGISTERED  ACADEMIC MEDICAL CENTERS.
(3)AS PARTOF THE CRIMINAL HISTORY RECORDS CHECK FOR AN EMPLOYEE, THE ENTITY  SHALL SUBMIT AN APPLICATION TOTHECENTRAL REPOSITORYWITH:
(I)TWO COMPLETE SETSOF THE EMPLOYEE’S LEGIBLE FINGERPRINTS; AND
(II)ANYFEE REQUIRED UNDER STATELAW FOR ACCESS TOSTATE CRIMINAL HISTORY  RECORDS.
(4)THE CENTRALREPOSITORY SHALL FORWARD TO THE EMPLOYEE, THE DISPENSING CENTER, AND THECOMMISSION THE EMPLOYEE’S CRIMINALHISTORY RECORD INFORMATION.
(5)INFORMATIONOBTAINED FROM THE CENTRAL REPOSITORY UNDER THIS SUBSECTION  IS CONFIDENTIALAND MAY NOT BE DISSEMINATED.
(6)(I)AN INDIVIDUAL WHO HAS BEEN CONVICTED OFSALE OFA CONTROLLED
DANGEROUS SUBSTANCE MAY NOT BE ISSUEDA REGISTRATION TO OPERATE A DISPENSING  CENTER, UNLESS THE CONVICTIONWAS FOR A VIOLATION OFFEDERALLAW RELATING TOSALE OFMARIJUANA FOR CONDUCT THAT IS LEGAL UNDER THIS SUBTITLE.
(II)AN INDIVIDUAL WHO HAS BEENCONVICTEDOFSALE OF A CONTROLLED DANGEROUS  SUBSTANCEMAY NOT BE AN EMPLOYEE OFA DISPENSING CENTER, UNLESS THE CONVICTION
WAS FOR A VIOLATION OFFEDERALLAW RELATING TOSALE OF MARIJUANA FOR CONDUCT  THAT ISLEGAL UNDER THIS SUBTITLE.
(III)AN INDIVIDUAL WHO HAS BEENCONVICTEDOFA FELONY MAY NOT BE ISSUED A  REGISTRATION TO OPERATE A DISPENSING CENTER UNLESS THE CONVICTION WAS FOR A  VIOLATION OFFEDERAL LAW RELATING TO THE SALE OF MARIJUANA FOR CONDUCT THAT IS LEGAL UNDERTHIS SUBTITLE.
(IV)AN INDIVIDUAL WHO HAS BEENCONVICTEDOFA FELONY MAY NOT BE AN EMPLOYEE  OFA DISPENSING CENTER UNLESS THE CONVICTION WAS FOR A VIOLATION OFFEDERALLAW RELATING TOTHESALE OFMARIJUANA FOR CONDUCT THAT IS LEGALUNDER THISSUBTITLE.
(C)EXCEPTIF THE ENTITY IS A REGISTERED ACADEMIC MEDICAL CENTER, AN ENTITY SEEKING TO BE EXEMPTFROMSTATE AND LOCAL CRIMINALPENALTIES FOR OPERATING A  DISPENSING CENTER OR REGISTERED GROWER UNDER THIS SUBTITLE SHALL REQUIRE EACH
EMPLOYEE OF THE ENTITY TO SUBMIT TO PERIODIC DRUG TESTING AS DETERMINED BY THE  COMMISSION IN REGULATIONS.
(D)(1)EXCEPT AS PROVIDED IN THIS SUBSECTION, THECOMMISSION SHALL ISSUE A  REGISTRATION TO OPERATE A DISPENSING CENTER OR DISPENSING PHARMACY IF:
(I)THEREQUIREMENTS OF THIS SECTION ARE MET;
(II)THECOMMISSION HAS VERIFIED THE INFORMATION CONTAINED IN THE  APPLICATION; AND
(III)THEAPPLICATION IS IN COMPLIANCE WITHALL REQUIREMENTS ISSUED BY THE COMMISSION.
(2)THE COMMISSION MAY REASONABLY LIMIT THE NUMBER OF DISPENSING CENTERS  STATEWIDE OR BY GEOGRAPHIC AREA.
(3)IF THE COMMISSION LIMITSTHE NUMBER OF DISPENSINGCENTERS, IT MAY DECIDE
WHICH TO ISSUE CERTIFICATES BY CONSIDERING THE STRENGTH OF PROPOSED DISPENSING  CENTERS’ PLANS, INCLUDING FOR SECURITY, PREVENTING DIVERSION,AND PROVIDING LOWER  COST OR FREE MARIJUANA TO QUALIFYING PATIENTS WITHLITTLE OR NO INCOME.
(4)THE COMMISSION SHALL APPROVE OR DENYAN APPLICATION WITHIN60 DAYS AFTER
RECEIPT OFA COMPLETED APPLICATION.
(5)THE COMMISSION SHALL ASSIGN TO EACH ENTITY THATHAS BEEN ISSUED A  REGISTRATION UNDER THIS SECTION A UNIQUE DISPENSING CENTER OR DISPENSING PHARMACY IDENTIFICATION NUMBER.
(6)A DENIAL OFAN APPLICATION SHALL BE CONSIDERED A FINAL AGENCY DECISION FOR PURPOSES OF JUDICIALREVIEW UNDER THE ADMINISTRATIVE PROCEDURE ACT.
(E)AN INDIVIDUAL WHO HAS BEENISSUED A REGISTRATION UNDER THIS SECTION SHALL DISPLAYTHE REGISTRATION AT THE DISPENSING PHARMACY OR DISPENSING CENTERAT ALL TIMES WHEN THE DISPENSING PHARMACY OR DISPENSING CENTER IS IN POSSESSIONOF MARIJUANA.
(F)A REGISTRATION HOLDERSHALL REPORTANY CHANGE IN INFORMATION TO THE COMMISSION NO LATER THAN 10 DAYS AFTER THE CHANGE.
(G)AN INDIVIDUAL WHO HAS BEENISSUED A REGISTRATION UNDER THIS SECTIONMAY  NOT:
(1)HOLD ANY OTHER REGISTRATION ISSUED UNDER THIS SUBTITLE, UNLESS THE  INDIVIDUAL IS A REGISTERED ACADEMIC MEDICAL CENTER; OR
(2)BE A CERTIFYING PHYSICIAN.
(H)ON OR BEFORE SEPTEMBER1,2012, THEMEDICALMARIJUANAOVERSIGHT COMMISSION, IN CONSULTATION WITH THE BOARD OF PHARMACY, THESTATE POLICE, AND  STAKEHOLDERS, SHALL DEVELOP REGULATIONSREGARDING THE PROCEDURES TO BE  FOLLOWED BY REGISTERED ACADEMIC MEDICAL CENTERS, DISPENSING PHARMACIES, AND  DISPENSING CENTERS IN DISPENSING, STORING, AND TRANSPORTING MARIJUANA UNDER THIS  SUBTITLE.
(I)(1)THE COMMISSION MAY ESTABLISHAFEE FOR RENEWAL APPLICATIONS AND  RENEWED REGISTRATIONS FOR DISPENSING CENTERS AND DISPENSINGPHARMACIES.
(2)THE COMMISSION SHALL GRANT OR DENYA RENEWAL BASED ON THE DISPENSING  CENTER ORDISPENSING PHARMACY’S PERFORMANCE, INCLUDING WHETHER ITHAS FOLLOWED  REGULATIONS, INCLUDING BY IMPLEMENTING APPROPRIATE PROCEDURES FOR SECURITYAND NON-DIVERSION.
(J)(1)THE SALE OF MARIJUANA MAY NOT BE ADVERTISED ON BILLBOARDS, TELEVISION, OR RADIO.
(2)THE COMMISSION MAY DEVELOP ADDITIONALRULES RESTRICTING THE TIME, PLACE, AND MANNERTHAT MARIJUANA SALES MAY BE ADVERTISED.
(3)RESTRICTIONS ON ADVERTISING SHALL NOT PREVENT APPROPRIATE SIGNS ON THE  PROPERTY OF THE REGISTERED DISPENSING CENTER OR LISTINGS INBUSINESS DIRECTORIES  INCLUDING PHONE BOOKS.
13-3008.
(A)(1)THE MEDICALMARIJUANAOVERSIGHT COMMISSION, IN CONSULTATION WITH STATE AND LOCAL LAW ENFORCEMENT, SHALLDEVELOP REGULATIONS PROVIDING FOR THE  ISSUANCE OFREGISTRYIDENTIFICATION CARDS TO QUALIFYING PATIENTS WHO:
(I) HAVE RECEIVED A WRITTEN CERTIFICATION FROM A CERTIFYING PHYSICIAN; OR
(II) ARE ENROLLED TOPARTICIPATE IN A REGISTEREDACADEMIC PROGRAM’S RESEARCH PROGRAM.
(2)THE COMMISSION MAY ESTABLISH ANAPPLICATION ORRENEWALFEETHAT MAY BE  BASED ON ASLIDING SCALE.
(3)THE COMMISSION SHALL ISSUE A REGISTRY IDENTIFICATION CARD TOA QUALIFYING  PATIENT WHO HAS BEENISSUED A VALID WRITTEN CERTIFICATION BY A CERTIFIED PHYSICIAN  OR WHO HAS BEEN CERTIFIED TO PARTICIPATE IN A MEDICAL MARIJUANAPROGRAM BYA  REGISTERED ACADEMIC MEDICAL CENTER.
(4)EACH QUALIFYING PATIENT SHALL SENDTHECOMMISSION:
(I)THE NAME, ADDRESS, AND DATE OF BIRTH OFTHE QUALIFYING PATIENT;
(II)A WRITTEN CERTIFICATION ISSUED BY THEPATIENT’S CERTIFYING PHYSICIAN OR  DOCUMENTATION FROM A REGISTERED ACADEMIC MEDICAL CENTER;
(III)THE NAME, ADDRESS, AND DATE OF BIRTHOFTHE QUALIFYING PATIENT’S PRIMARY CAREGIVER, IFTHE PATIENT WISHES TOHAVE A PRIMARY CAREGIVER;
(IV)AN APPLICATION ORRENEWAL FEE THATMAY BE BASED ON A SLIDING SCALE AS  DETERMINED BYTHECOMMISSION.
(V)IF THE QUALIFYING PATIENT WISHES TO HAVE A PRIMARY CAREGIVER, THEREASON  THAT THE PATIENT REQUIRES THE ASSISTANCE OF A CAREGIVER TOOBTAINMARIJUANA.
(B)(1)THE COMMISSION SHALL:
(I)APPROVE OR DENYAN APPLICATION ORRENEWAL WITHIN 30 DAYS OFRECEIPT OF THE APPLICATION OR RENEWAL;
(II)ISSUE A REGISTRY IDENTIFICATION CARD WITHINFIVE DAYS OFAPPROVINGTHE  APPLICATION OR RENEWAL;
(III)ENSURETHAT A PERSON IS NOT DESIGNATED AS A PRIMARY CAREGIVERFORMORE THAN FIVE (5) QUALIFYING PATIENTS.
(2)THE COMMISSION MAY DENYAN APPLICATION OR RENEWAL ONLY IFTHE APPLICANT FAILS TO PROVIDE THE INFORMATION REQUIRED UNDER THIS SECTION OR IFTHE COMMISSION DETERMINES THAT THE INFORMATIONWASFALSIFIED.
(3)THE COMMISSION SHALL DENYA REQUESTFOR A PRIMARY CAREGIVER IF:
(I)THEAPPLICANT FAILS TOPROVIDE THE INFORMATION REQUIREDUNDER THIS  SECTION;
(II)THECOMMISSION DETERMINESTHATTHE INFORMATION WAS FALSIFIED;
(III)THE QUALIFYING PATIENT DID NOTPROVIDE A CONVINCING REASON WHYHE OR SHE  NEEDED A PRIMARY CAREGIVER;
(IV)THE PRIMARY CAREGIVER IS ALREADY REGISTERED TO ASSISTFIVE PATIENTS; OR
(V)THE PRIMARY CAREGIVER HAS A CONVICTION THAT PRECLUDES PARTICIPATIONIN  THE PROGRAM.
(4)DENIALOFTHEAPPLICATION SHALL BE CONSIDERED A FINAL AGENCY DECISION FOR PURPOSES OF JUDICIALREVIEW UNDER THE ADMINISTRATIVE PROCEDURE ACT.
(C)(1)THE COMMISSION SHALL REQUIRE EACH APPLICANT SEEKING TO SERVE AS A
PRIMARY CAREGIVER TO APPLY TO THE CENTRAL REPOSITORY FOR A CRIMINALHISTORY RECORDS CHECK.
(2)THE COMMISSION SHALL PROVISIONALLY APPROVE ANAPPLICATION TO SERVE AS A  PRIMARY CAREGIVER PENDING THERESULTS OF A CRIMINAL HISTORY RECORDS CHECK.
(3)AS PART OF THE APPLICATION FOR THE CRIMINALHISTORYRECORDS CHECK, THE  APPLICANT SHALL SUBMIT TO THE CENTRAL REPOSITORY:
(I)TWO COMPLETE SETSOF THE APPLICANT’S LEGIBLE FINGERPRINTS TAKENON FORMS  APPROVED BY THE DIRECTOROF THECENTRAL REPOSITORY; AND
(II)ANYFEE REQUIRED UNDER STATELAW FOR ACCESS TOSTATE CRIMINAL HISTORY  RECORDS.
(4)THE CENTRALREPOSITORY SHALL FORWARD TO THE APPLICANT ANDTO THE COMMISSION THE POTENTIAL PRIMARY CAREGIVER’S CRIMINAL HISTORY RECORD INFORMATION.
(5)INFORMATIONOBTAINED FROM THE CENTRAL REPOSITORY UNDER THIS SUBSECTION  IS CONFIDENTIALAND MAY NOT BE DISSEMINATED.
(6)(I)AN APPLICANT WHO HAS BEEN CONVICTED OFPOSSESSION ORSALE OF A  CONTROLLED DANGEROUS SUBSTANCE MAYNOT SERVE AS A PRIMARY CAREGIVER, UNLESS THE  CONVICTION OCCURRED ON OR AFTER SEPTEMBER1,2012, AND WAS FOR A VIOLATION OF
FEDERAL LAW RELATING TO POSSESSION OR SALE OF MARIJUANA FOR CONDUCTTHAT IS LEGAL  UNDER THIS SUBTITLE.
(II)AN INDIVIDUAL WHO HAS BEENCONVICTEDOFA FELONY MAY NOT BE ISSUED A  REGISTRY IDENTIFICATION CARD TO SERVE ASA PRIMARY CAREGIVER.
(7)ON RECEIPT OF THECRIMINALHISTORY RECORDS CHECK FROM THE CENTRAL  REPOSITORY,THE SECRETARYSHALL NOTIFY THE APPLICANT INWRITING OFTHE APPLICANT’S  QUALIFICATION OR DISQUALIFICATION FOR SERVING ASAPRIMARY CAREGIVER.
(D)THE REGISTRY IDENTIFICATION CARD SHALL CONTAINTHE FOLLOWING INFORMATION:
(I)THE NAME, ADDRESS, AND DATE OF BIRTH OFTHE QUALIFYING PATIENT;
(II)THE NAME, ADDRESS,AND DATE OF BIRTH OFTHE QUALIFYING PATIENT’S PRIMARY  CAREGIVER, IF ANY;
(III)THE DATE OF ISSUANCE;
(IV)AN EXPIRATION DATE OF THE REGISTRYIDENTIFICATION, WHICHSHALL BE ONE  YEAR AFTER THE DATE OF ISSUANCE, UNLESS A DIFFERENT DATE IS INCLUDED ON THE  WRITTEN CERTIFICATION;
(V)PHOTO IDENTIFICATION OFTHECARDHOLDER;
(VI) A RANDOM IDENTIFICATION CARD NUMBER; AND
(VII)ANY OTHER INFORMATION PROVIDED FOR BY THE COMMISSION IN REGULATIONS.
(VIII) A PRIMARY CAREGIVER OR QUALIFYING PATIENT WHO HAS BEEN ISSUED A REGISTRY IDENTIFICATION CARD SHALL NOTIFY THE COMMISSION OF ANY CHANGE IN THE  PERSON’S NAME OR ADDRESS WITHIN 10 DAYS OF THE CHANGE OR THE REGISTRY IDENTIFICATION CARD SHALL BE CONSIDERED VOID.
(IX) 1. IF THERE IS A CHANGE IN THE STATUS OF A PATIENT’S QUALIFYING MEDICAL CONDITION THAT REQUIRES A CERTIFYING PHYSICIAN TO WITHDRAW THE PATIENT’S WRITTEN  CERTIFICATION OR THE QUALIFYING PATIENT’S REGISTERED ACADEMIC MEDICAL CENTER TO TERMINATE THE QUALIFYING PATIENT’S PARTICIPATION IN ITS PROGRAM, THE CERTIFYING
PHYSICIAN OR REGISTERED ACADEMIC MEDICAL CENTER SHALL PROVIDE WRITTEN NOTICE TO THE PATIENT AND THE COMMISSION WITHIN 10 DAYS OF BECOMING AWARE OF THE CHANGE.
2. ON RECEIPT OF THE NOTICE DESCRIBED IN SUBSECTION(B)(IX)(1.), THE COMMISSION  SHALL:
A. REVOKE THE PATIENT’S AND, IF APPLICABLE, THE PATIENT’S PRIMARY CAREGIVER’S  REGISTRY IDENTIFICATION CARD; AND
B. SEND THE PATIENT AND, IF APPLICABLE, THE PATIENT’S PRIMARY CAREGIVER A REVOCATION NOTICE REQUIRING THE IMMEDIATE RETURN OF ALL REGISTRY IDENTIFICATION  CARDS.
3. ON RECEIPT OF A REVOCATION NOTICE UNDER SUBPARAGRAPH 2 OF THE  SUBPARAGRAPH, A PATIENT AND, IF APPLICABLE, A PATIENT’S PRIMARY CAREGIVER SHALL:
A. IMMEDIATELY SEND THE COMMISSION OR OTHER ENTITY ISSUING REGISTRY IDENTIFICATION CARDS THE REGISTRY IDENTIFICATION CARD OF THE PATIENT AND, IF  APPLICABLE, THE PATIENT’S PRIMARY CAREGIVER; AND
B.HAVE 15DAYSTO DISPOSE OF ANY MARIJUANA IN THE PATIENT’S POSSESSION, BY  TRANSFERRING THE MARIJUANA TO A DISPENSING CENTER OR DISPENSING PHARMACY.
(E)THECOMMISSIONSHALLESTABLISH PROCEDURES FOR EACHREGISTERED
QUALIFYING PATIENT TO DESIGNATE A SINGLE DISPENSING CENTER OR DISPENSING PHARMACY ATA TIME WITH THE COMMISSION.
(F)(1)THE COMMISSION SHALL MAINTAIN A CONFIDENTIAL LIST OF THE INDIVIDUALS TO WHOM IT ISSUED REGISTRY IDENTIFICATION CARDS.
(2)THE NAMES OFINDIVIDUALS AND OTHER IDENTIFYING INFORMATION ON THE LIST:  (I)ARE CONFIDENTIAL;
(II)MAY NOT BE CONSIDERED A PUBLIC RECORD; AND (III)MAY NOT BE DISCLOSED EXCEPTTO:
1.AUTHORIZED EMPLOYEES OF THE COMMISSION AS NECESSARYTO PERFORMOFFICIAL DUTIES OFTHE COMMISSION; OR
2.AUTHORIZED EMPLOYEES OF STATE ORLOCAL LAW ENFORCEMENT, TO VERIFY THAT AN INDIVIDUAL WHO IS ENGAGED IN THE SUSPECTED ORALLEGED MEDICAL USE OFMARIJUANA  IS LAWFULLY INPOSSESSION OF A REGISTRYIDENTIFICATION CARD.LAW ENFORCEMENT WILL NOT BE ABLETO QUERYRECORDS FOR PERSONS NOT IMMEDIATELY BEING CONSIDERED IN  CASES OF SUSPECTED MARIJUANA MISUSEOR WHO PRESENTEDLAW ENFORCEMENT WITH THEIR REGISTRY IDENTIFICATION CARD.AUTHORIZED EMPLOYEES OFSTATEOR LOCAL LAW  ENFORCEMENTMAY PROVIDE A REGISTRYIDENTIFICATION NUMBER ASSOCIATEDWITH A REGISTRY IDENTIFICATION CARD AND RECEIVE VERIFICATION OFTHE NAME, ADDRESS, AND  CURRENTPROGRAM STATUSFOR THE PATIENT ASSOCIATED THE REGISTRY IDENTIFICATION  NUMBER.
13-3009.
(A) ANY OF THE FOLLOWING PERSONS ACTING IN ACCORDANCE WITH THE PROVISIONS OF THIS SUBTITLE MAY NOT BE SUBJECT TO ARREST, PROSECUTION, OR ANY CIVIL OR ADMINISTRATIVE PENALTY, INCLUDING CIVIL PENALTY OR DISCIPLINARY ACTION, BY A  PROFESSIONAL LICENSING BOARD, NOR BE DENIED ANY RIGHT OR PRIVILEGE, FOR THE MEDICAL USE OF MARIJUANA:
(1) A QUALIFYING PATIENT OR PATIENT’S PRIMARY CAREGIVER WHO HOLDS A VALID  REGISTRY IDENTIFICATION CARD AND IS IN POSSESSION OF AN ALLOWABLE AMOUNT OF USABLE MARIJUANA PURCHASED OR ACQUIRED IN ACCORDANCE WITH THE PROVISIONS OF THIS SUBTITLE;
(2) A REGISTERED GROWER OR A REGISTERED GROWER’S EMPLOYEE;
(3) IF A QUALIFYING PATIENT IS UNABLE TO DISPOSE OF MARIJUANA AND HE OR SHE  DOES NOT HAVE A CAREGIVER, A PERSON TRANSPORTING THE QUALIFYING PATIENT’S  MARIJUANA TO A DISPENSING CENTER OR DISPENSING PHARMACY;
(4)ADISPENSING PHARMACY THAT HOLDS A REGISTRATIONUNDER THISSUBTITLE OR A  DISPENSING CENTER ORAN EMPLOYEE OFA DISPENSING PHARMACY ORDISPENSING CENTER;
(5) A CERTIFYING PHYSICIAN;
(6) A REGISTERED ACADEMIC MEDICAL CENTER AND ITS STAFF; OR
(7) A LABORATORY CONDUCTING TESTING OF MEDICAL MARIJUANA, INCLUDING FOR  POTENCY AND CONTAMINANTS, OR AN EMPLOYEE OF A LABORATORY CONDUCTING TESTING OF MEDICAL MARIJUANA.
(B) THE POSSESSION OF, OR THE APPLICATION FOR, A REGISTRY IDENTIFICATION CARD  DOES NOT ALONE CONSTITUTE PROBABLE CAUSE TO SEARCH AN INDIVIDUAL OR THE PROPERTY OF AN INDIVIDUAL POSSESSING OR APPLYING FOR THE REGISTRY IDENTIFICATION CARD, OR
OTHERWISE SUBJECT THE INDIVIDUAL OR THE PROPERTY OF THE INDIVIDUAL TO INSPECTION  BY A GOVERNMENTAL UNIT.
(C) AN INDIVIDUAL MAY NOT BE SUBJECT TO ARREST OR PROSECUTION FOR  CONSTRUCTIVE POSSESSION, CONSPIRACY, OR ANY OTHER OFFENSE FOR BEING IN THE
PRESENCE OR VICINITY OF THE MEDICAL USE OF MARIJUANA AS ALLOWED UNDER THIS  SUBTITLE.
13-3010.
(A) (1) AN AGENT OF A DISPENSING PHARMACY OR A DISPENSING CENTER MAY SELL OR
DISPENSE AN AMOUNT OF USABLE MARIJUANA THAT DOES NOT EXCEED THE AMOUNT SET BY THE COMMISSION IN A 30-DAY PERIOD TO A REGISTERED QUALIFYING PATIENT OR THE  QUALIFYING PATIENT’S PRIMARY CAREGIVER IF THE INDIVIDUAL:
(I) PRESENTS A VALID REGISTRY IDENTIFICATION CARD;
(II) HAS IDENTIFIED THE DISPENSING CENTER OR DISPENSING PHARMACY AS THE SOLE
DISPENSING CENTER OR DISPENSING PHARMACY THAT THE PATIENT CAN RECEIVE MARIJUANA  FROM, IN ACCORDANCE WITH COMMISSION REGULATIONS.
(B) ON RECEIPT OF THE INFORMATION REQUIRED UNDER SUBSECTION (A) OF THIS SECTION, THE APPROVED DISPENSING PHARMACY OR DISPENSING CENTER SHALL VERIFY THE  INFORMATION PRESENTED.
(C) (1) EACH APPROVED DISPENSING PHARMACY AND DISPENSING CENTER SHALL MAINTAIN INTERNAL RECORDS OF EACH MARIJUANA DISPENSING TRANSACTION.
(II) THE RECORDS REQUIRED UNDER PARAGRAPH (1) OF THIS SUBSECTION SHALL INCLUDE:
(I) THE AMOUNT OF MARIJUANA DISPENSED;
(II) THE REGISTRY IDENTIFICATION NUMBER OF THE INDIVIDUAL TO WHOM THE  MARIJUANA WAS DISPENSED AND WHETHER THAT INDIVIDUAL WAS A QUALIFYING PATIENT OR
THE QUALIFYING PATIENT’S PRIMARY CAREGIVER;
(III)THESTRAIN OF MARIJUANA DISPENSED; AND (IV)THE DATE ANDTIME OFTHE TRANSACTION.
(3)A RECORD MAINTAINED UNDER THIS SUBSECTION:  (I)IS CONFIDENTIAL; AND
(II)MAY NOT INCLUDE NAMES OR OTHER PERSONAL IDENTIFYING INFORMATION.
(D)(1)A QUALIFYING PATIENT MAY BE REGISTERED AT ONLY ONE DISPENSING  PHARMACY OR DISPENSING CENTER AT ANYTIME.
(2)THE COMMISSION SHALL ESTABLISH PROCEDURES TO ALLOW A QUALIFYING PATIENT TO CHANGEHIS OR HER DESIGNATED DISPENSING PHARMACY OR DISPENSING CENTER FOR A  $15 FEE.
(3)THE COMMISSION MAY LIMIT THE NUMBER OFTIMES A QUALIFYINGPATIENT MAY  CHANGE A DESIGNATION OF A PHARMACY OR DISPENSING CENTER TO ONE TIME EVERY30 DAYS.
13-3011.
A PERSON WHO KNOWINGLY GIVES FALSE INFORMATION OR MAKESA MATERIAL
MISSTATEMENT IN AN APPLICATION FOR REGISTRATION OR IN AN APPLICATION FOR A  RENEWAL OFA REGISTRATION UNDER THISSUBTITLE IS GUILTY OFA MISDEMEANOR AND ON  CONVICTION IS SUBJECTTO IMPRISONMENT NOTEXCEEDING ONE YEAR, A FINE NOT  EXCEEDING $1,000, OR BOTH.
13-3012.
(A)THISSUBTITLE MAYNOT BE CONSTRUED TOAUTHORIZE ANY INDIVIDUAL TO ENGAGE  IN THE FOLLOWING, AND IT DOES NOT PREVENTTHE IMPOSITION OFANY CIVIL, CRIMINAL, OR OTHERPENALTIES FOR THE FOLLOWING:
(1)UNDERTAKE ANY TASK UNDER THE INFLUENCE OF MARIJUANA, WHEN DOING SO WOULD CONSTITUTE NEGLIGENCE OR PROFESSIONAL MALPRACTICE;
(2) OPERATE, NAVIGATE, OR BE IN ACTUAL PHYSICAL CONTROL OF ANY MOTOR VEHICLE, AIRCRAFT, OR BOAT WHILE UNDER THE INFLUENCE OF MARIJUANA;
(3) SMOKE MARIJUANA IN ANY PUBLIC PLACE;
(4) SMOKE MARIJUANA IN A MOTOR VEHICLE; OR
(5) SMOKE MARIJUANA ON A PRIVATE PROPERTY THAT:
(I) 1.IS RENTED FROM A LANDLORD; AND
2.IS SUBJECT TO APOLICY THATPROHIBITS THESMOKING OF MARIJUANA ON THE PROPERTY; OR
(II)IS SUBJECT TO A POLICY THAT PROHIBITS THE SMOKING OF MARIJUANA ON THE PROPERTYOFAN ATTACHED DWELLING ADOPTED BY ONE OFTHE FOLLOWING ENTITIES:
 1.THE BOARD OF DIRECTORS OFTHE COUNCIL OF UNIT OWNERS OF A    CONDOMINIUM REGIME; OR
 2.THE GOVERNING BODY OFA HOMEOWNER’S ASSOCIATION.
(B)THIS SUBTITLE MAYNOT BE CONSTRUED TOPROVIDE IMMUNITYTO A PERSON WHO  VIOLATESTHE PROVISIONS OFTHIS SUBTITLE FROM CRIMINAL PROSECUTION FOR A  VIOLATION OF ANY LAW PROHIBITING OR REGULATING THE USE, POSSESSION, DISPENSING, DISTRIBUTION, OR PROMOTION OFCONTROLLED DANGEROUS SUBSTANCES, DANGEROUS  DRUGS, DETRIMENTAL DRUGS, OR HARMFUL DRUGS, ORANY CONSPIRACY OR ATTEMPT TO COMMIT ANY OF THOSE OFFENSES.
13-3013.
NOTHING IN THIS SUBTITLE SHALL BE CONSTRUED TO REQUIRE A PUBLIC OR PRIVATE  HEALTH INSURER TO REIMBURSE AN INDIVIDUAL FOR THE COSTS ASSOCIATED WITH THE  MEDICAL USE OF MARIJUANA.
13-3014.
(A) BEGINNING OCTOBER 1, 2013, AND EACH OCTOBER 1 THEREAFTER, THE COMMISSION SHALL REPORT TO THE GOVERNOR AND, IN ACCORDANCE WITH § 2-1246 OF THE  STATE GOVERNMENT ARTICLE, THE GENERAL ASSEMBLY ON:
(1) THE NUMBER OF APPLICATIONS FOR REGISTRY IDENTIFICATION CARDS;
(2) THE NUMBER OF QUALIFYING PATIENTS AND PRIMARY CAREGIVERS REGISTERED;
(3) THE NATURE OF THE DEBILITATING MEDICAL CONDITIONS OF THE QUALIFYING  PATIENTS;
(4) THE NUMBER OF ACADEMIC MEDICAL CENTERS REGISTERED AND THE SCOPE OF THEIR PROGRAMS;
(5) THE ENTITIES RECEIVING REGISTRATIONS TO GROW MARIJUANA;
(6) THE ENTITIES RECEIVING REGISTRATIONS TO DISPENSE MARIJUANA;
(7) THE NUMBER OF REGISTRY IDENTIFICATION CARDS REVOKED;
(8) THE NUMBER OF REGISTRATIONS TO ENTITIES TO GROW OR DISPENSE MARIJUANA
REVOKED; AND
(9)THE NUMBER OF CERTIFYING PHYSICIANS PROVIDING WRITTEN CERTIFICATIONS FOR  PATIENTS.
(B)THE REPORT REQUIRED UNDER SUBSECTION(A) OF THIS SECTIONMAY NOT CONTAIN ANY IDENTIFYING INFORMATION OF QUALIFYING PATIENTS, PRIMARY CAREGIVERS, ENTITIES SELECTED TO GROW ORDISPENSE MARIJUANA,OR CERTIFYING PHYSICIANS.
(C) ON OR BEFORE OCTOBER 1, 2013, AND EVERY TWO YEARS THEREAFTER, THE COMMISSION SHALL REPORT TO THE GOVERNOR AND, IN ACCORDANCE WITH § 2-1246 OF THE  STATE GOVERNMENT ARTICLE, THE GENERAL ASSEMBLY ON:
(1) WHETHER THERE ARE SUFFICIENT NUMBERS OF DISPENSING PHARMACIES AND DISPENSING CENTERS TO MEET THE NEEDS OF REGISTERED QUALIFYING PATIENTS THROUGHOUT THE STATE;
(2) WHETHER THE NUMBER AND SCOPE OF ACADEMIC PROGRAMS AND THE NUMBER OF  CERTIFYING PHYSICIANS IS SUFFICIENT TO MEET THE NEEDS OF PATIENTS IN THE STATE;
(3) WHETHER ANY DISPENSING PHARMACY OR DISPENSING CENTER HAS CHARGED  EXCESSIVE PRICES FOR MARIJUANA THAT THE PHARMACY OR CENTER DISPENSED.
(4) ANY NEW AND EMERGING DOCUMENTED SCIENTIFIC EVIDENCE OF THE EFFICACIOUS MEDICAL USE OF MARIJUANA, INCLUDING SYMPTOMS OR CONDITIONS FOR WHICH MARIJUANA  MAY BE AN EFFECTIVE TREATMENT.
13-3015.
(A) THE MEDICAL MARIJUANA OVERSIGHT COMMISSION MAY ACCEPT FROM ANY  SOURCE GRANTS OR CONTRIBUTIONS TO BE USED IN CARRYING OUT THIS SUBTITLE.
(B) ANY FEES COLLECTED UNDER THIS SUBTITLE SHALL BE USED TO OFFSET THE COSTS OF THE COMMISSION’S ADMINISTRATION OF THIS SUBTITLE. FEES SHALL BE SET AT AN  AMOUNT HIGH ENOUGH TO ENSURE THAT THE TOTAL AMOUNT OF FEES ASSESSED, PLUS  CONTRIBUTIONS, AND GRANTS COLLECTED ARE SUFFICIENT TO COVER THE COSTS OF ADMINISTERING THIS SUBTITLE.
(C) (1) THE COMMISSION MAY DISTRIBUTE ANY FUNDS RECEIVED THAT EXCEED THE  AMOUNT OF FUNDING NEEDED TO FULFILL ITS DUTIES UNDER THIS SUBTITLE TO ACADEMIC  INSTITUTIONS OR REGISTERED ACADEMIC MEDICAL CENTERS IN MARYLAND TO STUDY THE
IMPACT OF THE MEDICAL MARIJUANA PROGRAM OR TO CONDUCT CLINICAL OR OBSERVATIONAL RESEARCH ON THE MEDICAL EFFICACY OF MARIJUANA, INCLUDING BUT NOT LIMITED TO:
(I) CLINICAL TRIALS;
(II) SELF-REPORTED INITIAL AND LONG-TERM EFFECTIVENESS AND SAFETY BY PATIENTS;
(II) PHYSICIAN REPORTS OF INITIAL AND LONG-TERM SAFETY AND EFFECTIVENESS;
(IV) ASSESSMENTOF SAFETY AND ACCEPTABILITY OF MEDICALMARIJUANA USE AMONG  THE GENERAL PUBLIC AND FAMILYMEMBERS OF QUALIFYING PATIENTS;
(V) IMPACT ON PATIENT ILLICIT AND PRESCRIPTION DRUG USE BEFORE, DURING, AND  AFTER USE OF MEDICAL MARIJUANA;
(VI) IMPACT ON THE QUALITY OFLIFE OF THE PATIENT OR THE PATIENT’S FAMILY;
(VII)IMPACT ON ILLICIT DRUG USE IN THE STATE AND ASSOCIATED CRIME STATISTICS.
(2)THE COMMISSION MAY DELIVER ANY FUNDS RECEIVED THATEXCEED THE AMOUNT OF FUNDING NEEDED TOFULFILL ITS DUTIES UNDER THISSUBTITLE THAT REMAIN AFTER  DISBURSEMENTS ARE MADE UNDERSUBSECTION(1) TOTHE GENERAL FUND.
SECTION 3. AND BE IT FURTHER ENACTED, THAT THIS ACT SHALL TAKE EFFECT IMMEDIATELY.
     
  Medical Marijuana Model Program Workgroup   
Membership
64     
 Dr. Joshua M. Sharfstein Secretary of Health and Mental Hygiene and Chair of Workgroup
Delegate Dan Morhaim Representative of the Maryland House of Delegates 
Delegate Kathleen Dumais  Representative of the Maryland House of Delegates 
Senator David Brinkley  Representative of the Maryland Senate
Senator Jamie Raskin  Representative of the Maryland Senate
Deborah Miran  Public Member
Dr. Nancy R. Cohen   Maryland Chapter of National Council on Alcoholism and Drug 
Dependency
Dr. Paul Celano   Physician   Oncologist 
Dr. Joseph G. Liberto   Physician   Addiction Psychiatrist
Dr. Trudy Hall  Physician   Pain Management 
Philip H. Cogan  Pharmacist
Dr. Ryan Vandrey  Scientist
Lynn S. Billing  Registered Nurse
Karen O’Keefe  Lawyer 
Major Kevin M. Anderson   Maryland Chiefs of Police
Dario J. Broccolino  Maryland State’s Attorneys Office
Major Sam Billotti, IV  Maryland Sheriffs’ Association 
Michael Young  Maryland Fraternal Order of Police 
Medical Marijuana Model Program Workgroup - Membership           
 
65

Posted in: Blog